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ABSTRACT 
The focus of my graduate research is on the development of simplified and ultrasensitive 
methods for quantifying low abundance biomarkers with the ultimate goal of developing robust 
tools for advancing disease diagnosis. In recent years there has been an immense expansion in 
the identification of sensitive and specific indicators of disease. As our understanding of these 
biochemical parameters continues to advance, the ability to quantify low abundance biomarkers 
from small samples sizes has become increasingly important to continue expanding the range of 
available disease indicators. Further, as medical diagnostics continues to transition to point-of-
care testing, the development of simplified protocols capable of producing rapid results has been 
a main element limiting the development of portable devices. Together, each of these factors will 
play a critical role in the analysis of clinical samples for the purpose of providing more robust 
diagnostic and prognostic information to patients suffering from diseases ranging from infectious 
disease to cancer, metabolic, autoimmune, and gastrointestinal disorders. This thesis focuses on 
two independent projects which aim to address these limitations through the design of improved 
methods for the quantification of microRNA (miRNA) and protein in biological fluids.   
The first of my projects relates to the ultrasensitive detection of miRNA, one of the most 
exciting emerging classes of biomarkers.  In recent years, miRNA in blood circulating have been 
identified as robust indicators of a variety of diseases. Despite extensive research into the 
potential impact of miRNAs as clinical indicators, state of the art methods remain dependent on 
incredibly complex and time consuming techniques. Together, these limitations have been main 
factors extending research timelines and precluding the development of POC assays. Main 
factors contributing to the complexity of existing tests include the dependence on reverse 
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transcriptase, DNA ligase, and PCR steps, each of which necessitate time consuming reagent 
handling as well as  1-2 h incubations.  
To addresses these issues, my research has focused on the development of an efficient 
RNA amplification technique which uses enzymatic chemical labeling to generate densely 
labeled double stranded products that are then labeled with fluorescent probes. Individual 
molecules are then directly counted using total internal reflection fluorescence microscopy, as 
opposed to conventional indirect methods using the polymerase chain reaction (PCR). This 
technology provides a fundamental framework for the development of an ultrasensitive miRNA 
detection method which allows for the absolute and direct quantification of miRNAs in clinical 
samples. This thesis demonstrates enzymatic labeling of miRNA with fluorescent probes as well 
as the optimization of surface attachment and probe labeling methods. Ultimately this research 
concludes with the successful detection of labeled miRNA, establishing a framework for 
advancing the sensitivity of this method toward the fundamental level of digital single molecule 
counting.  
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CHAPTER 1: GENERAL INTRODUCTION TO MICRO-RNA DETECTION 
1.1 OVERVIEW OF MICRO-RNA AS A BIOMARKER 
In recent years, circulating blood borne micro-ribonucleic acids (miRNAs), a class of 
∼22 nucleotide-long non-coding ribonucleic acids (RNAs), have been identified as accurate 
indicators of a variety of diseases. Despite extensive research into the potential impact of 
miRNAs as clinical indicators, state of the art methods of detection and quantification each have 
their own strengths and weaknesses. The purpose of this introduction is to provide an overview 
of the physiological importance of miRNA production and regulation, to analyze the 
advancements in the use of miRNA as a clinical biomarker, and to discuss the advantages and 
drawbacks of the most common methods of miRNA quantification and data analysis.  
miRNAs are cellular regulatory elements that were first identified in Caenorhabditis 
elegans in the early 1990s.1,2 Since this groundbreaking work, miRNAs have been identified as 
regulatory elements in organisms ranging from plants and animals to single-celled eukaryotes, as 
well as viruses.3 In particular, miRNAs are known to play important roles in regulating gene 
expression related to development, cell proliferation, apoptosis, metabolism, morphogenesis as 
well as in pathological processes.4 Considering the role of miRNAs in each of these processes, 
miRNAs have emerged as valuable clinical indicators of disease. 
While miRNAs are the most prominent form of small RNAs, there are a number of 
different small RNAs which act to regulate genes through the suppression of genetic material as 
well as transcripts. These small RNAs include miRNAs, small interfering RNAs (siRNAs), and 
PIWI-interacting RNA (piRNA) from Drosophila piwi (P-element-induced wimpy testes) 
genes.5,6 Each of these small RNAs are characterized by a size ranging from 20-30 nucleotides, 
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association with the Argonaute family of proteins, as well as their role in gene silencing. Of these 
small RNAs, miRNAs are by far the most common in the majority of cell types, and are the most 
extensively characterized in healthy tissues as well as for disease phenpotypes.7 Current 
estimates indicate that nearly 30,424 mature miRNA products have already been annotated, with 
simple eukaryotes such as Caenorhabditis elegans and Drosophila melanogaster having 434 and 
466 miRNAs currently catalogued, respectively, while complex eukaryotes such as humans 
having as many as 2,588 regulatory miRNAs identified to date.8  
 
1.2 MICRO-RNA PRODUCTION, MATURATION, AND MECHANISM OF ACTION  
miRNA precursors known as pre-miRNAs are initially produced using RNA polymerase 
II in the cell nuclease, where transcription is regulated through RNA Pol II‑associated 
transcription factors as well as through epigenetic regulators such as DNA methylation and 
histone modification.9,10 Following the initial transcription of miRNAs, long single stranded 
caped and polyadenylated primary miRNA (pri-miRNA) can be >1 kb in length. These pri-
miRNAs are then processed by the multiprotein Microprocessor complex composed of two 
proteins known as Drosha and Prasha, which together processes pri-miRNA into hairpin 
strictures ranging from ~60-100 base pairs (bps) known as precursor-miRNA (pre-miRNA).10,11 
Pre-miRNAs are then transported out of the nucleus through the Ran-GTP dependent export 
carrier, Exportin-5.12 Following pri-miRNA processing and export from the nucleus, cytoplasmic 
pre-miRNAs are cleaved into their final ~22 bp dsRNA state by the RNase III enzyme, DICER.  
Once miRNA is completely processed, it is free to act as guide molecule for gene 
silencing through translational repression and mRNA cleavage.9 This translational regulation is 
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mediated through miRNA binding by an Argonaute protein followed by the assembly of a RNA-
induced silencing complex (RISC).13 The RISC complex is then able to recognize target mRNAs 
for gene silencing through the dsDNA binding of the loaded miRNA with complementary 
regions on the 3′-untranslated region (3’-UTR) of a target mRNA. RISC complexes can then 
facilitate gene silencing through a variety of mechanisms, but the two most common methods 
involve the deadenylation and subsequent degradation of mRNA as well as the inhibition of 
translational initiation.  
Surprisingly, it has been shown that miRNA mediated recognition of target genes can 
occur even in the absence of perfect base pairing.14 In fact, it has been shown that only 2-7 base 
pairs of complementarity are necessary to facilitate gene silencing.15 This imperfect base pairing 
allows a single miRNA to play a role in the regulation of as many as thousands of proteins in 
tandem.14 It is presently estimated that nearly 2,588 human miRNAs are encoded in the human 
genome, and that each likely plays a role in the regulation of between 100 and 200 target genes, 
together regulating the protein production of at least a third of human genes.8,13 
Considering the importance of miRNAs in genetic regulation, the control of miRNA production 
and activity has been a very active research area. To date, a variety of methods for miRNA 
regulation have been identified, including the transcriptional regulation of miRNA genes, 
miRNA processing by Drosha, control of nuclear export of pre-miRNA, Dicer processing of pre-
miRNA, as well as through the control of the Argonaute and RISC complex activity.10 
Modulation of each of these regulatory methods is of particular interest as a result of the 
correlation between miRNA activity and disease progression. Specifically, the role of the 
demonstrated role of miRNA regulation in cancer progression and recurrence has been of intense 
interest 16. 
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1.3 MICRO-RNA UTILIZATION AS A CANCER BIOMARKER  
One of the earliest works identifying miRNA as a potential biomarker for cancer 
detection was the work out of the lab of Dr. Todd Golumb, wherein the concentration of 217 
mammalian miRNAs were quantified in 334 biopsy samples from a variety of tumor types.17 By 
analyzing a variety of miRNAs, it was found that the majority of miRNAs (59.5%) were 
downregulated in a variety of cancer types. This finding was consistent with the hypothesis that 
downregulation of miRNAs may play a causative role in tumor development and persistence by 
helping to promote cell division rather than cell differentiation. When investigated further, it was 
found that global downregulation of miRNA through miRNA processing gene knockdown in 
mice resulted in a decreased survival in effected mice. The impact of miRNAs on neighboring 
cells has even been shown to cause tumor formation in healthy cells.18 
In addition to playing an integral role in cancer development within individual cells, a 
growing amount of research has indicated that miRNA may play an important role in cell-cell 
communication through exosomes, microvesicles, and direct transfer between cells.19 Exosomes 
are endosome-derived lipid vesicles which have been identified as important mediators for 
transferring proteins and RNAs between cells. Recent studies have demonstrated that tumor 
derived exosomes (TEX) mediated miRNA transfer plays an integral role in effecting the 
proliferation, angiogenesis, migration, and immune suppression of cells within close proximity to 
tumor cells.19–21 Like exosomes, microvesicles are derived from the cell membrane, but are 
formed from the plasma membrane rather than the endosome.22 As with exosomes, microvesicles 
have been shown to shed from tumor cells and to play an integral role in modulating tumor 
microenvironments in a variety of cancer types.23,24 As a final method of modulating neighboring 
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cells using miRNAs, tumors are known to directly transfer miRNAs to neighboring cells through 
gap junctions.25,26 
 
1.4 MICRO-RNA USE FOR DIAGNOSIS OF SOLID TUMORS  
Considering the role of miRNAs in cancer development and progression, there has been 
an immense interest in the potential of miRNAs to act as cancer biomarkers. Early studies on 
tumor miRNA expression indicated that as few as 200 miRNAs could be utilized to classify 
human cancers from paraffin embedded tissue samples.17,16 In addition to identifying key genes 
involved in a cancers tumorigenesis, studies have also shown that cellular miRNA can be used to 
identify the tissue and cell type of origin.27 Further, the investigation of miRNAs expression in 
solid tumors has resulted in the identification of novel cancer subtypes with immense prognostic 
potential.28,17 In addition to demonstrating the capability to diagnosis cancerous tissues based on 
miRNA profiles, numerous subsequent studies have demonstrated the prognostic potential of 
miRNA detection. In particular, studies have demonstrated the development of miRNA panels 
which are predictive of cancer progression in a variety of cancer types including: lymphocytic 
leukemia (CLL), lung cancer, kidney cancer, pancreatic cancer, and urothelial carcinoma.29–33 
While the vast majority of current diagnostic and prognostic information derives from 
analyzing tissue biopsies, the necessity to isolate these tissues dramatically decreases the clinical 
feasibility of using these strategies. In particular, tissue biopsies are not typically performed 
unless there is already substantial reason to believe that a tumor has formed, eliminating much of 
the potential as a strategy for detection, prior to diagnosis. Further, the technically demanding 
and invasive nature of conventional solid biopsies make these methods far less practical for 
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monitoring pathological changes that necessitate periodic analysis to evaluate the impact during 
or after a therapeutic regimen. As a result, the majority of miRNA detection research has 
transitioned to focusing on the analysis of biomarkers within accessible liquid biospecimens, 
including whole blood, serum, saliva, sputum, and urine. 34,35 
 
1.5 MICRO-RNA DETECTION AS A CIRCULATING CANCER BIOMARKER  
While the detection of miRNA in purified cells provides enriched and abundant miRNA 
for analysis of cellular processing, the invasive nature of tissue biopsies and a priori knowledge 
necessary for successful extraction of tumor tissue dramatically decreases the clinical value of 
this strategy. Fortunately, a variety of studies have demonstrated that miRNA maintains stability 
within biological fluids, allowing for its use as a minimally invasive diagnostic and prognostic 
biomarker.36 Further, it has been shown that miRNAs in serum exhibit remarkable stability 
compared to synthetic miRNA, a fact believed to be attributed to their existence within 
microvesicles which convey protection from endogenous nucleases.36,37 Considering these 
factors, circulating miRNAs have emerged as a prominent emerging class of biomarkers.  
One of the most promising applications of circulating miRNA is in the early detection 
and analysis of cancers. To date, studies have identified circulating miRNAs capable of 
identifying each of the most common types of cancer including lung cancer, breast cancer, 
colorectal, prostate, pancreatic, ovarian, esophageal cancer, and B cell lymphoma among 
numerous other examples.38–45 In addition to measuring the abundance of target miRNA, single 
nucleotide polymorphisms (SNPs) and the existence of alternative splice isoforms have also 
emerged as important indicators of cancer presence and progression. In each of these instances, 
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the detection and characterization of circulating miRNA provides a robust and noninvasive 
method for detecting and characterizing cancers at an early stage. 
Beyond providing an improved means of detecting cancer, quantification of circulating 
miRNAs provide a method by which the effects of cancer treatment can be evaluated on a day to 
day basis to provide acute prognostic information which can be used to modulate treatment 
strategy to ultimately reduce the risk of cancer remission. As with diagnostic tests, circulating 
miRNA levels have been utilized to gauge patient prognosis in cancers ranging from lung cancer 
and lymphocytic leukemia to colorectal cancer. 30,46–48 Over the last several years there has been 
an acceleration in the discovery of circulating miRNA biomarkers, emphasizing the importance 
of this emerging biomarker for the early stage detection and prognostic evaluation of cancer 
treatment strategies.  
 
1.6 MICRO-RNA USE AS A NON-CANCER DISEASE BIOMARKER  
In addition to the use of miRNA for applications in cancer detection and prognosis, 
miRNA has been identified as a robust indicators of a variety of other diseases including 
cardiovascular disease, cardiac hypertrophy, chronic obstructive pulmonary disease, sarcoidosis, 
periodontitis, pancreatitis, myocardial infarction, as well as a variety of neurodegenerative 
disorders such as multiple sclerosis, Alzheimer’s disease (AD), Parkinson’s disease (PD), and 
frontotemporal dementias (FTD).37,49–52 Each of these disease associated miRNAs as well as 
those associated with various cancers have been amalgamated in the human miRNA-associated 
disease database (HMDD), a continuously growing index which has 10,368 entries that include 
572 miRNA genes and 378 diseases from 3,511 papers as of June 14th 2014. 53  
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1.7 OVERVIEW OF COMMERCIAL METHODS FOR MICRO-RNA DETECTION 
Considering the immense regulatory role in biological processes as well as the wide 
variety of diagnostic applications of miRNA biomarkers, the development of highly specific and 
ultra-sensitive methods for miRNA detection in complex matrices has been of immense interest 
to academic research and medical diagnostics alike. In general, these methods have focused on a 
variety of advancements in 3 main technological areas including microarrays, sequencing-based 
methods, and quantitative reverse transcription polymerase chain reaction (RT-qPCR).54 The 
purpose of the following sections is to review the strengths and weaknesses of multiplexed and 
singleplex miRNA detection methods, to highlight areas where the balance of cost, precision, 
accuracy and sample quantity make specific methods more practical than others, to review 
miRNA data analysis methods, and to identify areas where there remains demand for improved 
performance.  
 
1.8 MULTIPLEXD METHODS: MICRO-RNA MICROARRAYS 
DNA microarrays were first developed in 1988 by a group assembled by Dr. Alex 
Zaffaroni, which ultimately founded the company Syntex to commercialize the technique.55 This 
technology became the first technique which allowed for high throughput multiplexed DNA 
analysis.56 Since its invention, nearly 40,000 publications have been made using this technology 
with hundreds of thousands of independent experiments. Microarrays also represent one of the 
first techniques used to enable the comparison of miRNA expression levels between different 
cell types, cells at various developmental and differentiation stages, changes in expression during 
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disease states, and the impact of chemical and environmental changes on cells17,57. miRNA 
microarrays achieve this multiplexed detection by visualizing fluorescently labeled miRNAs 
hybridized to complimentary capture probes spatially separated on a solid support.54 
The overall technique of performing a DNA microarray experiment is a relatively simple 
process. The first step of this process is to covalently modify a surface with hundreds to 
thousands of oligonucleotide probes arrayed spatially using a spotter or direct on-substrate 
synthesis. Arrays are prepared with each oligonucleotide probe designed complementary to 
known sequences of interest.58 Samples are then prepared by extracting, purifying, and enriching 
miRNAs within a sample, and directly labeling the miRNAs with one or several fluorophores. 
Prepared samples are then added to the array and allowed to hybridize to complimentary 
oligonucleotide probes.59 The array is then washed, scanned with a laser capable of exciting 
fluorescent tags, and fluorescence is recorded using an imaging platform.60 
While this method represented one of the first techniques used for the multiplexed 
quantification of miRNAs, a major issue to date has been the variability in miRNA sequence and 
the dramatic variation in potential melting temperatures as well as the stringency of binding and 
wash conditions necessary to achieve specific results for each miRNA. Variations in melting 
temperature between different miRNAs within a sample correspond to differences in capture 
sequence binding affinity, ultimately manifesting in different steady state equilibrium and 
inconsistent extents of miRNA surface binding. This factor prevents the direct comparison of 
miRNA abundance even within the same sample, and makes microarrays dramatically less 
quantitative than other techniques. While this issue can be partially addressed by designing 
capture probes with similar predicted binding affinity or by amplifying duplex stability through 
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the use of locked nucleotides or 2′-O-(2-methoxyethyl)-(MOE) oligoribonucleotides, 
microarrays are still considered to be less quantitative than alternative methods.61–65  
A second major challenge in the use of microarrays in the detection of miRNAs has been 
the dependence on a labeling step. The most common method of labeling miRNA directly using 
T4 RNA ligase to attach one or several fluorophore labeled nucleotides to the 3’ end of 
miRNA.66 While this technique provides a direct means of labeling miRNA, the low label 
density and the lack of signal amplification inherently limits the sensitivity of this technique. To 
address this limitation, advancements in labeling have been developed including the use of 
amplification methods such as rolling circle amplification (RCA) as well as the use of a variety 
of labels including fluorescent dNTPs, fluorescent probes, Quantum Dots, molecular beacons,-
binding dyes, and enzymatic signal production. 67–71 While these methods have shown promise in 
pushing detection sensitivity to the fundamental digital level of single-molecule detection in 
academic publications, the necessity to include a labeling step is known to introduce various 
biases into multiplexed data sets.64,68,72 As an added challenge, extensive protocols, a high degree 
of technical expertise, and laborious data acquisition has prevented the commercial adoption of 
many alternative labeling and data acquisition strategies to date73. 
One of the earliest barriers to acquiring quality microarray data stemmed from variations 
in early laser scanners.74 In a review of several image analysis systems, it was found that UCSF 
Spot algorithm proved better at identifying log expression ratios as well as low intensity spots 
when compared to GenePix.75 In addition to these tools, each of the major microarray companies 
has developed tools optimized for their respective scanners. The main purpose of these 
techniques is to identify the location of spots, to determine where signal is too low to be 
considered significant, and ultimately to acquire pixel level intensity data and convert this into 
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miRNA abundance data. This data acquisition occurs in tandem with signal normalization, 
analytical techniques for improving microarray data quality and eliminating sources of signal 
variation inherent in microarrays. 
Many different techniques have been proposed for signal normalization, but they can be 
broadly categorized into global and intensity-dependent normalization.76 Global intensity 
dependence-based methods were the first and simplest of normalization methods. This method 
assumes a constant proportionality factor across all the genes in an array and does not account 
for any variations in signal within an array.77 This method allows microarray data to be 
compared between samples regardless of the amount of DNA used in the array. Alternatively, 
intensity dependent methods allow for variations within an array to be accounted for. 
Unsurprisingly, research comparing these methods has demonstrated that intensity dependent 
methods perform significantly better than global normalization techniques, and that non-linear 
techniques did not perform significantly better than linear methods. The most common tools used 
in industry include BRB-ArrayTools, SNOMAD, LOWESS, as well as those provided by 
Agilent and Affymetrix76.  
Despite technical challenges, miRNA microarrays are one of the most commercially 
available methods for the multiplexed detection of miRNAs, with a multitude of companies 
providing miRNA profiling arrays including Affymetric, Genosensor, Agilent, Exiqon, 
Invitrogen, Nanostring, Illumina, and LC Biosciences. While these methods do have some 
drawbacks, they are currently the least expensive method of screening a large number of 
miRNAs for qualitative expression profiling. As an added benefit, microarrays frequently 
necessitate a lower sample amount (100-1000 ng total RNA) than qPCR (500 ng) or sequencing 
(500-5000 ng).60 As a final benefit, miRNA microarray have extensively validated protocols with 
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well-established data analysis methods. While microarrays do not provide the most quantitative 
results, they remain an attractive option for drastically multiplexed studies where existing 
miRNA sequences are known, where cost is a consideration, and where there are not serious 
repercussions as a result of false positive results.  
1.9 MULTIPLEXD METHODS: RNA SEQUENCING 
One of the most exciting new techniques emerging in miRNA detection is direct RNA 
sequencing (RNAseq), which leverage the capabilities of next-generation sequencing platforms 
for miRNA detection and quantification.78 There are a number of major advantages to RNAseq 
compared to DNA microarrays and RT-PCR. Among the most important of these advantages is 
the ability for RNAseq to be used without a priori knowledge of target sequences. Microarrays 
and RT-PCR each require this information in order to design probes specific to DNA targets, a 
process which limits these methods to detecting the quantity of known targets included within a 
test panel. Further, miRNAs with minor sequence variations are frequently indistinguishable 
from each other using hybridization-based methods. Unlike microarray and RT-PCR-based 
miRNA detection, RNAseq allows all miRNA present within a sample to be quantified 
regardless of the sequence.  
This capacity makes sequencing-based methods uniquely capable of identifying novel 
biomarkers in a manner never previously possible. This benefit is particularly useful in the 
analysis of samples from sources which are not yet thoroughly characterized as well as for the 
identification of novel miRNA biomarkers in common sample types. Perhaps more importantly, 
this allows for the identification of novel miRNA isoforms. While we do know alternative 
miRNA processing occurs, research on the identification and function of these alternative 
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isoforms necessitates that new isoforms can be identified and effectively differentiated, a factor 
which can present an immense problem for other platforms. 
While there was initially some skepticism about the quantitative capacity of RNA-seq, 
Malone et al. analyzed the same samples using both RNA-seq and microarray analysis in order to 
compare the expression measurements between these platforms.79,80 Results of this comparison 
showed that both techniques showed outstanding agreement. This analysis found that array data 
was compressed at high levels due to there being a limited number of probes on a microarray, 
which can become saturated. There were also a large range of lowly expressed nucleotides which 
were found to be detectable in microarrays, but not in RNA-Seq despite there being increased 
scatter58. An alternative analysis of these same techniques indicated that RNA-seq has a far 
larger dynamic range as well as lower sensitivity in very low and very high expression levels 
60,81. These studies indicate that there remains some contention in the field, but that RNA-seq 
performs at least as well as arrays, and that both methods show a large degree of agreement for 
intermediately expression levels.  
RNA sequencing is achieved by converting all miRNA within a sample to target DNA by 
reverse transcriptase using universal primers. target DNA is then ligated to adapters and 
immobilized on surfaces. Any of a number of commercial second generation DNA sequencing 
technologies can then be used including: next-generation sequencing (NGS) (Illumina), 454 
pyrosequencing (Roche), SOLiD Next-Generation Sequencing (ThermoFisher), and HiSeq 
(Illumina) sequencing. While advancements in DNA sequencing methods have made this process 
dramatically less expensive, faster, and more accurate in recent years, sequencing remains the 
most expensive of the commonly employed miRNA detection methods. While RNseq does 
provide immense benefits, it also requires substantially more input RNA (500-5000 ng), 
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generates vast quantities of data that require extensive effort and long times to analyze, and 
typically cannot achieve the same sensitivity as RT-PCR-based methods.60 
 
1.10 QUANTITATIVE REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION 
While the methods discussed so far provide convenient methods for analyzing many 
miRNAs in tandem, relatively high cost and an overabundance of data to be interpreted make 
them less appropriate for singleplex applications. A third common method for detecting miRNAs 
is RT-qPCR. RT-qPCR is considered to be the most sensitive and specific method for detecting 
miRNAs in samples, and represents the most common method used for sensitive miRNA 
detection in academic research as well as for clinical applications.82 RT-pCR is performed in a 
multi-step process involving the conversion of miRNA into DNA templates followed by the 
exponential amplification of DNA templates similar to conventional qPCR. DNA amplification 
is monitored in real time, allowing for direct comparison between samples and control wells on 
the same plate. qPCR reactions are frequently multiplexed using a variety of reaction reservoirs 
with primers specific to different miRNAs on the same microtiter plate or within microfluidic 
cards.60 
One of the most important factors in achieving uniform miRNA amplification is the 
consistent conversion of miRNA into template DNA. This process can be achieved using a 
variety of methods including the use of Poly (A) tail additions and the use of stem-loop 
primers.60 When stem loop primers are used, as in the TaqMan RT-PCR, primers bind to the 3’ 
end of miRNA and are used to generate complimentary DNA using reverse transcriptase.60 
Quantitative PCR is then performed to amplify templates in the presence of probes containing 
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fluorophores in close proximity to fluorescent quenchers. As the synthesis proceeds, Taqman 
probes hybridized to ssDNA are hydrolyzed by polymerase 3’ exonuclease activity. This process 
results in an increase in sample fluorescence resulting from the release of previously quenched 
fluorophores, allowing for the real time analysis of amplification progression.60,83 
A second method for detecting miRNAs involves the polyadenylation of the 3’ end of 
miRNAs followed by reverse transcription using a Poly-d(T) primer.84 Template DNA is then 
amplified using primers specific to the miRNA and the Poly A tail. Quantitative PCR is then 
used in conjunction with the dsDNA intercalating dye, SYBR Green, which has dramatically 
amplified fluorescence in the presence of dsDNA.60  
As with microarray-based miRNA detection, a main hurdle in qPCR reactions has been 
variations resulting from the annealing temperatures of different primers. Unsurprisingly, similar 
strategies can be employed to address this issue including the normalization of melting 
temperatures as well as the use of LNAs.85 A second method for addressing this problem has 
been to use universal primers instead of primers specific to a target miRNA sequence. Using 
universal reverse transcription removes variations resulting from the varying binding affinity of 
different miRNAs, allowing for dramatically improved consistency in miRNA detection.86  
Another problem with RT-qPCR base methods is the need for a relative ratio as a metric 
for quantification. Without the availability of a “stable” control miRNA sequence to normalize 
levels of a miRNA of interest, this phenomenon precludes the potential for direct comparison 
between studies.87 As a result, there remains a demand for direct counting-based methods to 
exactly quantify the abundance of miRNA present within samples.  
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Despite these challenges, RT-PCR has emerged as the gold standard for miRNA 
detection. A main reason for the extensive adoption of RT-PCR-based methods is the 
unparalleled sensitivity and specificity. In addition, RT-PCR has benefited from extensive 
existing infrastructure as well as the expertise many labs have in quantitative PCR used for other 
applications. While each of these factors make RT-PCR an attractive medium cost option for 
miRNA quantification, there are several drawbacks to the technology. One of the main 
drawbacks of RT-PCR is that, as with microarrays, a priori knowledge of target miRNA 
sequences is needed. This prevents the use of RT-PCR for large discovery projects seeking to 
identify novel biomarkers. A second drawback comes from the limitations on the extent of 
multiplexing possible using the microplate format as compared with microarray and sequencing-
based methods. Despite these factors, RT-PCR will likely remain the workhorse of miRNA 
detection for the foreseeable future as a result of the intermediate cost, extensive infrastructure, 
and existing expertise.  
 
1.11 MICRO-RNA DATA ANALYSIS METHODS 
Beyond providing incredibly robust direct comparison data between miRNA expression 
profiles in different biological states, analytical tools for organizing differentially expressed 
miRNA-based on known similarities in activity have been developed in order to grant insight 
into the biological significance of transcriptomic processes associated with the studied events. 
Together, these methods have made these tests invaluable tools in academic research as well as 
for the development of commercial products.  
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As an initial step in this process of identifying the significance of the variations in the 
concentration of nucleic acids, differentially expressed genes (DEGs) must be identified.88 Some 
of the most common tools include Mev, SAM, EDGE, and iArray.89,90 MeV, TIGR 
MultiExperiment Viewer, uses a non-parametric t-test in order to find maximal differences in 
average expression between two groups and to minimize variation in expression within a group. 
SAM, alternatively, uses repeated permutations of data to determine significance of expression 
changes based on a false positive rate as well as a fold change parameter selected by users. 
Similarly, EDGE uses user selected significance parameters to find differentially expressed 
genes, but applies an Optimal Discovery Procedure (ODP) in order to estimate an optimal rule. 
Finally, iArray uses a two-step process where differential analysis is done on one data set, 
followed by the identification of DEGs consistently present between multiple data sets. In a 
comparison of 4 of these methods, it has been found that SAM is the most effective of these 
strategies and that it can be applied to a wide variety of datasets.90 
Once miRNA data has been collected, normalized, and used to identify differentially 
expressed genes, there remains an incredibly immense task of interpreting this data. In order to 
identify trends in these enormous data sets, clustering techniques are used to find similarly 
regulated genes with related roles.91 Clustering techniques were initially developed for text 
mining and information retrieval applications as well as for searching through large data sets. It 
is only within the last two decades that these techniques have begun being applied to the analysis 
of genetic data. There are a large number of clustering algorithms, each of which required 
evaluation for use in specific applications. In order for this comparison to be conducted, both 
internal quality metrics which compare the similarity of items within a group as well as external 
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quality measures which compare groups produced by clustering techniques to known cases are 
needed.  
The main methods used for this clustering include agglomerative hierarchical clustering 
and partitional K-means clustering. The earliest of these methods to be developed was 
agglomerative hierarchical clustering. Hierarchical clustering can be seen as a bottom up 
approach, where the algorithm begins with a series of single points which are then merged to the 
most similar pairs until all points are included in a single structure. This can be visually 
represented in a tree like diagram called a dendrogram. While this method does provide the 
benefit of identifying smaller clusters of co-expressed genes, it has been shown to be more 
sensitive to noise, outliers, and spherical clusters than K-means clustering. This method also 
requires that users select which regions to define as clusters, a process which can introduce the 
potential for the introduction of user biases into the data, a factor which can worsen the existing 
problem of users emphasizing and interpreting the relevance of gene clusters based on their 
initial hypotheses rather than independent biological significance.  
The second main class of clustering is partitional K-means clustering, which can be 
considered to be a top down approach. In these methods, a user defines an optimal number of 
clusters (k) and each individual point is organized into clusters at once. In general, K centroids 
are selected, points are assigned to the closest centroid, centroid centers are found considering 
new points, and this process is repeated until there is no change. Main benefits of this technique 
include increased sensitivity to spherical clusters, increased independence in cluster formation, 
and improved sensitivity as compared to hierarchical methods.  
One main problem with this method is, however, that effectiveness is dependent on the 
selection of the correct number of clusters. To address this problem, a number of methods have 
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been developed to select the optimal number of clusters for a given data set prior to initiating K-
clustering. Another problem with partitional K-clustering is that each gene typically can only be 
included in one cluster, even if it has biological significance in multiple processes. This issue 
was addressed using a method called Fuzzy Heuristic Partitioning, which allows each gene to be 
considered in multiple clusters. This allows the grouping of genes participating in multiple 
activities to be grouped in a far more effective fashion. As a final advancement, algorithms for 
excluding genes with weak relationships to members of a group have also been developed. Each 
of these algorithms have been employed in a system referred to as the DAVID bioinformatics 
resource, which is a free tool and among the most advanced of existing clustering methods.92 
 
1.12 COMPARISON OF EXISTING MICRO-RNA DETECTION METHODS  
In recent years, an incredible number of miRNAs have been identified as significant 
clinical biomarkers for a variety of diseases.29–33,37,49–52 To address the research and clinical 
demand for effective methods of measuring miRNAs, a variety of tools have emerged for 
miRNA detection, with miRNA microarrays, RT-PCR, and RNAseq being the most common 
commercial methods. While microarrays provide an established method with existing equipment 
infrastructure and relatively inexpensive cost per experiment, low sensitivity, the necessity to 
specify targets a priori, and the propensity for false positive results make microarrays less 
applicable to projects necessitating quantitative results or the identification of novel targets. 
Alternatively, RT-PCR provides the gold standard of sensitivity, but is more labor intensive and 
costly than microarray-based methods. Finally, RNA-seq provides the unique capacity to identify 
novel miRNAs, but costs substantially more than other methods, requires additional input 
sample, and does not provide the sensitivity of RT-PCR.  
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While there are a large number of potential benefits to RNAseq over microarrays and RT-
PCR, there are a number of reasons why transition away from microarrays and RT-PCR has not 
occurred more rapidly. One such reason is that small to intermediate sized arrays can still be 
substantially cheaper than RNAseq, though improvements in sequencing technology will likely 
result in significantly decreased cost in the coming years. Until this point, increased cost may 
also act as a deterrent to gaining necessary sequencing depth and to groups choosing to conduct 
multiple biological replicates. Another benefit of DNA microarray technology is that biases in 
array data are well understood and there exist sophisticated experimental and analytical methods 
for dealing with these problems. In comparison, these same methods remain largely in 
development for RNAseq. 
While there are some areas which still could benefit from additional research, RNA-seq 
has a myriad of benefits which give it clear advantages over other commercial technology. This 
is particularly the case for large data sets, for samples that are not yet thoroughly annotated, and 
in instances where there is potential for quantifying the expression of alternative splice isoforms. 
These benefits are likely to result in academic and pharmaceutical labs transitioning to RNA-seq 
in coming years. While a large portion of exploratory research will likely undergo this transition, 
there will almost certainly remain niche applications where specific targets are being detected, 
where a large number of samples are valued over transcript detection depth, and where existing 
equipment and familiarity with analysis algorithms deter the transition to RNA-seq.  
As opposed to miRNA detection for research and pharmaceutical development, clinical 
applications of miRNA detection are likely to focus on a smaller number of well-established 
indicators, with sensitivity, specificity, assay and equipment cost, and speed being main factors 
driving adoption. Considering each of these factors, the high sensitivity and specificity of RT-
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PCR likely make it the most attractive option for hospitals with laboratories capable of 
conducting these tests.  
  A final emerging market within the miRNA detection industry is the point of care 
detection industry. While there are no devices currently in use for detecting circulating miRNA, 
emerging research into the potential impact of miRNA biomarkers for rapid disease screening, 
diagnosis, or prognosis has driven an immense interest in the development of such devices. As 
with medical applications leveraging laboratory technologies, these tests will necessitate the 
highest levels of sensitivity and specificity while also demanding rapid test times and simple 
protocols compatible with automated devices. While existing methods have not been capable of 
achieving these ends as a result of complexity and delay resulting from dependence on reverse 
transcriptase, DNA ligase, and PCR steps, there are a variety of emerging methods which 
leverage the simplicity of microarray like detection platforms.  
As tools for transcriptomic continue to advance, RNA-seq will likely become the 
predominant method for screening for discovery research and pharmaceutical experimentation. 
Despite this fact, the practical benefits of microarray and RT-PCR-based technology make each 
superior options for specific applications. The multiplexed nature of microarrays, for example, 
make them well suited for multiplexed analysis of a predetermined set of targets. Alternatively, 
RT-PCR is particularly useful for research and clinical applications which demand high 
sensitivity without necessitating the detection of multiple targets in tandem. As technology 
continues to advance, it is likely that these platforms will provide the framework for developing 
ever improving methods capable of detecting miRNAs in clinical applications where they can be 
used to diagnose diseases ranging from cancer to neurodegenerative disorders.  
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CHAPTER 2: DEVELOPMENT OF AN ULTRASENSITIVE MICRO-RNA DETECTION 
METHOD 
2.1 OVERVIEW OF ENZYMATIC MICRO-RNA LABELING 
Circulating miRNAs in blood have been identified as robust indicators of diseases 
ranging from cancer to Parkinson’s disease.31–33,37,46,49–52,93 Despite extensive research into the 
potential impact of miRNAs as clinical indicators, state of the art methods remain dependent on 
complex techniques which are difficult to miniaturize, have off-target binding or amplification, 
and provide indirect measurements which do not allow for ultrasensitive miRNA detection. 
Together, these limitations have been main factors precluding the development of point-of-care 
(POC) assays, limiting the sensitivity if miRNA detection, and preventing direct comparisons 
between studies. Main factors contributing to the limitations of existing tests include the 
dependence on reverse transcriptase, DNA ligase, and PCR steps, each of which necessitate time 
consuming reagent handling as well as 1-2h incubations.  
The present work aims to addresses these issues using by labeling miRNA with 
fluorophores so that they can be directly counted using single-molecule imaging. This process 
enzymatically extends the miRNA with labeled nucleotides to yield numerous fluorophores on 
the same molecule, providing a robust signal for single-molecule detection with total internal 
reflection fluorescence microscopy (TIRFM). Together, these strategies provide a framework for 
a simplified, rapid, and extremely sensitive method of detecting miRNA in clinical samples.  
A schematic of this process is shown in Fig 2.1, with assays performed on a glass surface 
(Fig. 2.1). As an initial step, miRNA is captured through the hybridization of miRNA with a 
complementary sequence on the 5’ end of the plate bound capture DNA. Surfaces are then 
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washed to remove any unbound miRNA as well as any other molecules capable of contributing 
to assay background signal. A cocktail containing a polymerase reaction buffer, unlabeled-
dNTPs, biotin labeled-dNTPs, and a polymerase is then added to the solution. This cocktail 
facilitates the enzymatic extension of the miRNA primer through the incorporation of labeled 
and unlabeled nucleotides at the 3’ end of the miRNA primer, resulting in dense labeling of the 
miRNA with biotin. Following this process, the surface is washed a second time to terminate the 
reaction and remove reaction components including any residual labeled nucleotides capable of 
contributing to background fluorophore binding.  
 
Figure 2.1. Diagram of enzymatic labeling of miRNA. Figure one illustrates capture DNA bonding to a glass 
surface, the capture of miRNA present within a sample, the binding of DNA polymerase, incorporation of biot-
dUTPs into DNA using enzymatic labeling of miRNA, and fluorophore labeling of DNA to create highly fluorescent 
DNA products. 
 
In the final step, streptavidin-labeled fluorophores are added to the solution to allow each 
miRNA to produce highly fluorescent individual signals that can be independently detected 
through imaging (Fig. 2.1). Labeling by binding between a dye-labeled streptavidin (a tetrameric 
protein) and biotin (a small molecule) is one of the most common labeling strategies in 
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biological assays. Biotin-streptavidin binding represents the strongest natural noncovalent 
interaction with a Kd of 4X10
-14 M, a factor which allows for nearly irreversible attachment of 
labels without requiring very large label concentrations.94 Further, the broad availability of 
streptavidin-labeled fluorophores lends itself to a wide variety of potential imaging conditions, 
and allows a multitude of potential labels to be evaluated.  
As an initial application of this platform, a prostate cancer miRNA biomarker was 
selected as a model system. Our collaborators at Mayo Clinic (Manish Kohli) and the Medical 
College of Wisconsin (Liang Wang) have previously identified exosomal miR-375 miRNAs in 
blood as a prognostic biomarker for prostate cancer.95 In addition, miR-375 has been 
independently shown to be correlated with prostate cancer metastasis.96 By measuring the 
abundance of miR-375 at different time point during treatment, it has been shown that miR-375 
is significantly correlated with prostate cancer survival with a hazard ratio of 2.69 with a 95% 
confidence interval of 1.52–4.77. Importantly, these clinical correlations were made by 
measuring the relative ratios of miR-375 and a “control” miRNA (miR-30a-5p) using qPCR, 
which is necessary to the indirect nature of qPCR, for which calibration to concentration is 
problematic. We hypothesize that eventually our platform technology would not require such 
assay controls due to the direct nature of molecular quantification through counting. As a result 
of this compelling data, it has been hypothesized that regular monitoring of miR-375 during 
chemotherapy administration could allow for an assessment of therapy effectiveness to allow for 
adjusted treatment strategy when necessary. As a result, miR-375 was selected as an initial target 
for assay development.  
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2.2 MATERIALS AND METHODS 
2.2.1 Oligonucleotide Design 
 DNA oligonucleotides were designed with a 22-base miRNA capture region 
complementary to the target miR-375 miRNA located on the 3’ end of the capture 
oligonucleotide (Table 2.1). This orientation design allowed DNA synthesis on the 
complementary strand starting at the 3’ end of the bound miRNA. A 66-base synthesis region 
was designed to reduce the formation of self-dimers using 13 CTAGG repeats as well as an 
additional cytosine residue on the 3’ end (A=adenine, G=guanine, C=cytosine, T=thymine). 
Amine, biotin, or dibenzocyclooctyl (DBCO) DNA modifications were included on the 5’ end of 
the capture DNA to adhere DNA to solid supports.  
Oligo name Sequence 
Target DNA sequence TTTGTTCGTTCGGCTCGCGTGA 
Target miRNA sequence rUrUrUGrUrUCGrUrUCGGCrUCGCGrUGA 
Compliment DNA sequence TCACGCGAGCCGAACGAACAAA 
Scrambled DNA sequences GACACGGCAATACGAACGACAC 
Scrambled miRNA GrUGrUCGrUrUCGrUArUrUGCCGrUGrUC 
Biotin Capture DNA 
/5Biosg/CTAGGCTTGGCTTGGCTTGGCTAGGCTTGGCTTGGCTTGGCTAGGCTTGG
CTTGGCTTGGCTAGGCTCACGCGAGCCGAACGAACAAA 
Amine Capture DNA 
/5AmMC6/CTAGGCTAGGCTAGGCTAGGCTAGGCTAGGCTAGGCTAGGCTAGGCT
AGGCTAGGCTAGGCTAGGC TCA CGC GAG CCG AAC GAA CAA A 
DBCO TEG Capture 
/5DBCOTEG/ ACTTT ACTTT ACTTT ACTTT ACTTT ACTTT ACTTT ACTTT ACTTT 
ACTTT ACTTT ACTTT ACTTT AC TCA CGC GAG CCG AAC GAA CAA A 
Mock Capture DNA 
/5AmMC6/CTAGGCTAGGCTAGGCTAGGCTAGGCTAGGCTAGGCTAGGCTAGGCT
AGGCTAGGCTAGGCTAGGC GACACGGCAATACGAACGACAC 
Template Complement 
Strand 
TTT GTT CGT TCG GCT CGC GTG ACT TAT CTT ATC TTA TCT TAT CTT ATC TTA 
TCT TAT CTT ATC TTA TCT TAT CTT ATC TTA TCT TAT C 
Biotin target DNA /5BiosG/TTTGTTCGTTCGGCTCGCGTGA 
Fluorescein miRNA /56-FAM/rUrUrU rGrUrU rCrGrU rUrCrG rGrCrU rCrGrC rGrUrG rA 
50% GC Capture DNA 
ACTTC ACTCC ACTTC ACTCC ACTTC ACTCC ACTTC ACTCC ACTTC ACTCC 
ACTTC ACTCC TCA CGC GAG CCG AAC GAA CAA A 
20% GC Capture DNA 
ACTTT ACTTT ACTTT ACTTT ACTTT ACTTT ACTTT ACTTT ACTTT ACTTT 
ACTTT ACTTT ACTTT AC TCA CGC GAG CCG AAC GAA CAA A 
TYE563 DNA Biotin  /5BiosG/TTTTTTTTTTGCTGGAATTCGTCGTTTTTTTTTT/3TYE563/ 
TYE563 DNA Amine /5AmMC6/TTTTTTTTTTTTTTTTTTTTTTTTTTGCTGGAATTCGTCG/3TYE563/ 
Cy5-DNA-Biotin /Biotin/Cy5/GCTGGAATTCGTCG3’ 
Table 2.1. Linker Oligonucleotide Sequence. All DNA Oligos were purchased by Integrated DNA Technologies. Each 
base is represented by the corresponding letter abbreviation, with N representing degenerate mixed bases. 5biosG and 
3Bio represent biotin modifications on the 5’ and 3’ ends of oligos respectively. 5AmMC6 and iUniAmM represent 
5’ and internal primary amine modifications. 56-FAM represents a 5’ fluorescein modification.  
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2.2.2 DNA stock resuspension, quantification, and storage 
DNA oligonucleotides were all purchased from Integrated DNA Technologies 
(Coralville, Iowa). Stocks were resuspended in nuclease free water following a 5min 
centrifugation at 5000g. DNA was analyzed with a Nanodrop 1000 (Thermo Scientific, 
Waltham, MA) with concentration quantified based on absorbance at 260 nm and purity 
characterized based on A260/A280 ratio. All stocks were stored at -20 ºC prior to use. 
2.2.3 DNA synthesis reactions 
Capture DNA was initially mixed with either target DNA designed as a DNA analogue of 
the target or miRNA to a desired concentration. Samples were then heated to 60 ºC for 10min 
and allowed to cool to room temperature. Reactions were then prepared with 0.1U/uL DNA 
Polymerase I Large (Klenow) Fragment (New England Biolabs, M0210S), 1X Reaction Buffer, 
100 μM dNTPs (Life Technologies, 00303953). For labeling reactions, either Cyanine5 (Cy5) 
conjugated 2'-deoxyguanosine-5'-triphosphate (dGTP) (Cy5-dGTP) (PerkinElmer, NEL583001), 
Cy5 conjugated 2'-deoxyuridine 5'-triphosphate (dUTP) (Cy5-dUTP) (Enzo Life Sciences, ENZ-
42502), Biotin-11-dUTP (ThermoFisher, R0081), or C8-Alkyne-dUTP (Jena Biosciences, CLK-
T05-XL) were added at a final concentration of 100 μM along with each of the other 3 dNTPs. 
Reactions were then spun down and incubated for 1h at 37 ºC unless otherwise indicated. 
Following synthesis reactions, mixtures were heated to 75 ºC for 10min to deactivate the 
polymerase. Reactions were then stored at -20 ºC until use.  
2.2.4 Native polyacrylamide gel electrophoresis (PAGE) 
Criterion TBE Polyacrylamide Gels (15% ) (BIO-RAD, 3450055) were run in 1X Tris-
borate-Ethylenediaminetetraacetic acid (TBE) Buffer. 5 uL of synthesis samples were prepared 
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with 1 uL 6X Blue/Orange Loading Dye (Promega, G1881). Samples were then loaded on gels 
and ran for 1h at 100V. Gels were then removed and incubated in TBE buffer containing a 
1:10,000 dilution of SYBR® Gold Nucleic Acid Gel Stain (ThermoFisher, S11494) with shaking 
for 1h at room temperature. Gels were then visualized using a Bio-Rad Gel Doc XR+ System 
with ultraviolet (UV) illumination. Cy5 imaging was conducted on a ChemiDoc MP Imaging 
System with Image Lab Software with DyLight 650 nm illumination and a Red Epi 695/55 
Filter.  
2.2.5 SYBR green microplate assay  
In detect synthesized DNA, synthesis products were initially diluted 50X in sterile TBE 
buffer. Synthesis products were then mixed with SYBR® Green I Nucleic Acid Gel Stain 
(ThermoFisher, S7563) at a 1:2,500 fold dilution for 10min at room temperature to allow for 
SYBR dye binding. Samples were then loaded into black 96-well microtiter plates, and 
fluorescence was detected using a SpectraMax M2 Multi-detection reader with excitation at 485 
nm excitation and 508 nm emission wavelength unless otherwise indicated.  
2.2.6 15% MOPs urea PAGE 
15% MOPS-Urea Gels (10 mM MOPs, 2.5 mM sodium acetate, 0.5 mM 
Ethylenediaminetetraacetic acid  (EDTA), 7M Urea, 15% (v/v) 40% acrylamide:bis-acrylamide, 
0.07% (w/v) APS, 0.035%(v/v) TMED) were prepared immediately prior to usage. 5 uL of 
synthesis samples were then mixed with a denaturing buffer to a final concentration of 10 mM 
MOPs, 2.5 mM NaOAc, 0.5 mM EDTA, 7.33% formaldehyde, 4M Urea, 0.5X MOPs, and 1X 
Blue/Orange Loading Dye (Promega, G1881). Samples were then denatured for 10min at 65 ºC 
prior and immediately loaded onto the gel. Samples were then run at 50 V for 30min and 150 V 
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for 75min. Gels were then removed and incubated in TBE buffer containing a 1:10,000 dilution 
of SYBR® Gold Nucleic Acid Gel Stain (ThermoFisher, S11494) with shaking for 1h at room 
temperature. Gels were then visualized using a Bio-Rad Gel Doc XR+ System with UV 
illumination.  
2.3 RESULTS AND DISCUSSION: GEL ELECTROPHORESIS OF ENZYMATIC MICRO-
RNA LABELING 
As an initial step in demonstrating the feasibility of the proposed protocol, the capacity to 
synthesize DNA on the designed capture oligonucleotides was validated. This was achieved 
using the Klenow fragment of E. coli polymerase I, a polymerase known to have RNA dependent 
5′→3′ polymerase and 3′→5′ exonuclease (proofreading) activity without the 5′→3′ exonuclease 
activity present in the full Polymerase I enzyme97. Further, the Klenow fragment is known to be 
capable of incorporating labeled dNTPs including those labeled with Cy3, Cy5, biotin, and 
alkynes.98,99 Reactions were initially conducted using target DNA primers with a sequence 
corresponding to that of the target DNA using recommended conditions and an incubation for 1h 
at 37 ̊C.  
Following DNA synthesis, reactions products were visualized using native 
polyacrylamide gel electrophoresis (PAGE) and visualization with the dsDNA-binding dye 
SYBR green (Fig. 2.2). Results of this evaluation showed bands corresponding to the 88 bp 
capture oligo alone in wells corresponding to reactions without synthesis reagents. When target 
DNA was added, a band shift was observed, confirming that target DNA capture was achieved 
(Fig. 2.2, Lanes 1-4). Additionally, this experiment demonstrated that synthesis was achieved 
only in the presence of dNTPs, target DNA, capture DNA, and polymerase, with no synthesis 
observed in wells corresponding to controls without each of these components (Fig. 2.2, Lanes 1-
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13). As a final finding of this experiment, it was shown that synthesis occurred in a dose 
dependent fashion, with progressively more dsDNA product being produced when 25 nM, 50 
nM, 75 nM, or 100 nM target DNA was present (Fig. 2.2, Lanes 9-13).  
 
 
Figure 2.2. DNA Synthesis Evaluation with PAGE. 15% Criterion Urea-TBE Gel was run for 1h at 200V. The gel 
was then stained with SYBR Green at 10,000 fold dilution in TBE Buffer. A (+) sign indicates the presence of 
indicated reagents at standard reaction conditions (100 nM Capture DNA, 100 nM target DNA, 100 μM mixed 
dNTPs, 0.1 U/uL klenow polymerase). A (-) sign indicates the absence of indicated reagents. Numerical values 
indicate target DNA and miRNA concentrations in nanomolar units. A low molecular weight DNA ladder was used 
with standards at indicated molecular weights. 
 
 While gel electrophoresis provides a convenient method for visualizing DNA, it does not 
provide a very high-throughput means of monitoring reactions. As an added limitation, 
conventional DNA dyes including Ethidium Bromide (EtBr) and SYBR green dye require 
relatively large volumes of sample (10-20 uL, 100 nM) in order to effectively visualize ssDNA 
templates. While this is not a substantial issue when working with inexpensive reagents, the high 
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cost of modified dNTPS makes this strategy far less attractive than more cost effective and high 
throughput alternatives for monitoring DNA synthesis.  
2.4 RESULTS AND DISCUSSION: SYBR MICROPLATE ASSAY EVALUATION OF 
ENZYMATIC MICRO-RNA LABELING 
 As an initial method of monitoring the production of dsDNA, a nanodrop 
spectrophotometer (Thermo Scientific) was used to evaluate if changes in absorption could be 
used to quantify the extent of dsDNA production. These experiments take advantage of 
phenomenon known as the hyperchromic shift, where the ssDNA has been shown to exhibit a 
greater absorption than the corresponding double stranded DNA (dsDNA).100,101 Using a 
nanodrop spectrometer, very low concentrations of DNA can be analyzed in seconds using only 
microliter volumes of samples. By leveraging these tools in conjunction with the change in 
absorbance of synthesis samples, it was hypothesized that the extent of synthesis could be 
monitored in a rapid and convenient fashion. Upon initial analysis, large signals were observed 
in all samples. Further evaluation indicated that the primary cause of this background signal was 
a result of a large signal derived from dNTPs present within the reaction samples (Fig. 2.3). As a 
result, this strategy was abandoned as a means of monitoring reaction parameters.  
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Figure 2.3. Nanodrop Evaluation of DNA Synthesis Products. Sample absorbance at 260 nm was taken using a 
NanoDrop 1000 Spectrophotometer. Data points and error bars represent the mean and standard deviation of DNA 
synthesis samples analyzed in triplicate.  
 
 As a secondary high throughput and sensitive method for detecting DNA synthesis, a 
microplate assay utilizing the double stranded DNA specific dye SYBR green I was used. While 
the-binding dye ethidium bromide has been shown to exhibit a fluorescence enhancement of 
almost 4 fold upon DNA-binding, SYBR Green shows a remarkable >1000 fold enhancement 
upon binding to dsDNA.102–104 Further, SYBR Dyes have been shown to bind dsDNA with a Kd 
over a 100 fold lower than that of EtBr, with SYBR dyes binding with a Kd of 45.0 nM 
compared to ethidium bromide which binds with a Kd of 5556 nM.104 Additionally, SYBR green 
has been shown to be dramatically less mutagenic than ethidium bromide, making it far safer to 
handle and more conducive to the development of a user friendly assay.  
 In order to detect synthesized DNA using this protocol, enzymatic labeling of miRNA 
was conducted as described in the materials and methods. Synthesis products were then mixed 
with SYBR Green I and incubated to allow SYBR green to intercalate between dsDNA base 
pairs (Fig. 2.4). Fluorescence enhancement resulting from the presence of dsDNA was then 
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measured using a fluorescence spectrophotometer. This simple method allowed for a secondary 
means of validating reaction synthesis and confirming PAGE results in a quantitative manner.  
 
Figure 2.4. Diagram of enzymatic miRNA synthesis analysis with SYBR green I assay. Schematic illustrates the 
capture of miRNA present within a sample, the binding of DNA polymerase, incorporation of biot-dUTPs into DNA 
using enzymatic miRNA synthesis, selective intercalation of SYBR green, and the detection of highly fluorescent 
DNA products.  
 
 As an initial means of evaluating the potential of the SYBR green microplate assay, the 
optimal emission wavelength for detecting successful DNA synthesis was identified using 
scanning fluorescence spectroscopy with a fixed emission wavelength of 485 nm. Results of this 
optimization indicated that dsDNA synthesis could be easily detected, with an optimal signal to 
background ratio generated at an emission wavelength of 508 nm (Fig. 2.5). Further, evaluation 
of synthesis products as well as controls corresponding to each of the synthesis components 
indicated that dsDNA synthesis could be easily differentiated (Fig. 2.6). Following the 
identification of the ideal assay detection wavelength, the optimal sample dilution was evaluated 
and detection was found to be robust with 2-6% CV even at 50 fold dilution with a final dsDNA 
concentration of 2 nM. While this sensitivity is far from the diagnostic sensitivity ultimately 
needed, it provides a rapid and convenient means of evaluating synthesis samples using 10X less 
volume than a corresponding PAGE gel with a fraction of the cost and hands on time.  
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Figure 2.5. Scanning fluorescence spectroscopy. Scanning florescence spectroscopy was conducted in black 96 well 
plates using a SpectraMax M2 Multi-detection reader with excitation at 485 nm. 
 
Figure 2.6. SYBR Green I microplate assay. Florescence spectroscopy was conducted in black 96 well plates with 
SpectraMax M2 Multi-detection reader with excitation at 485 nm and emission at 508 nm. Samples imaged are at a 
1:50 dilution of DNA synthesis products in TBE Buffer. 
 
Once the SYBR Green I microplate assay parameters had been optimized, the assay was 
used to evaluate the impact of dNTP concentration on DNA synthesis. dNTP concentration is 
one of the most important parameters due to the use of labeled nucleotides which will be a main 
determinant in background signal. This is especially important because each nucleotide is 
typically present at micromolar concentrations, 1000X higher than even the maximum miRNA 
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concentration being detected. As a final factor, it is known that the reduction of dNTP 
concentration within a reaction mixture can cause replication stalling, inhibition, and arrest of 
DNA synthesis.105  
Evaluation of experimental results demonstrated that a plateau in dsDNA synthesis was 
achieved at a concentration of 316 μM, but that 87% efficiency of dsDNA production could be 
achieved at a concentration of 100 μM (Fig. 2.7). These findings were surprising considering that 
while the overall capture oligo is 88 bp in length, the extension region alone is a mere 66 bp 
(13A, 13T, 14G, 26C). With a reaction concentration of 100 nM, this indicates that anticipated 
dNTP consumption (0.13 μmol dATP, 0.13 μmol dTTP, 0.14 μmol dGTP, 0.26 μmol dATP) is 
nearly 100X lower than the amount present in the reaction mixture (31.6 μmol per dNTP). 
Considering that the overall dNTP concentration is depleted by less than 10% even with optimal 
synthesis, the most likely explanation for this finding is that dNTP binding kinetics at lower 
concentrations prevent the rapid association of dNTPs with the polymerase resulting in the arrest 
of DNA synthesis and dramatically reduced dsDNA production.105 
 
Figure 2.7. Evaluating the effect of dNTP concentration of dsDNA synthesis. SYBR Green I microplate assay. 
Florescence spectroscopy was conducted in black 96 well plates with SpectraMax M2 Multi-detection reader with 
excitation at 485 nm and emission at 508 nm. Data points and error bars represent the mean and standard deviation 
of DNA synthesis samples analyzed in triplicate. 
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As a second reaction parameter optimized, the reaction temperature was evaluated to 
determine if improved efficiency could be derived at higher temperatures. While the suggested 
reaction temperature for the Klenow polymerase is 37 ºC, it was initially hypothesized that 
increased temperature could improve reaction efficiency. Results of synthesis at 37 ºC, 47 ºC, 
and 57 ºC were each evaluated for DNA and miRNA initiated synthesis using PAGE gels (Fig. 
2.8). Results of this analysis indicated that both DNA and miRNA mediated synthesis provided 
nearly identical results regardless of reaction temperature.  
 
Figure 2.8. Evaluation of the effect of reaction temperature on miRNA and target DNA Synthesis. Non-denaturing 
15% Criterion TBE Gel was run for 1h at 200V. The gel was then stained with SYBR Green at 10,000 fold dilution 
in TBE Buffer. A (+) sign indicates the presence of indicated reagents at standard reaction conditions (100 nM 
Capture DNA, 100 μM mixed dNTPs, 0.1 U/uL klenow polymerase), 100 nM target DNA or 100 nM miRNA). A(-) 
sign indicates the absence of indicated reagents. Numerical values for reaction temperature are in ºC. A low 
molecular weight DNA ladder was used with standards at indicated molecular weights. 
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This finding along with the absence of bands corresponding to capture DNA alone in any 
reaction wells strongly suggested that reactions were continuing to completion in all cases. 
Notably, Klenow polymerase DNA synthesis reaction rates are known to be largely dependent on 
the kinetics of dNTP association rate rather than the enzyme kinetics.106 Beyond confirming 
reaction completion, this finding implies a large degree of flexibility for modulating reaction rate 
by changing reaction temperature to increase dNTP association and DNA synthesis.  
Once an optimal reaction temperatures were identified, DNA synthesis reactions were 
conducted as described in the materials and methods using target DNA as well as miRNA as 
target analytes added to reaction mixtures at a concentration gradient. PAGE analysis of these 
reaction products provided the first evidence that miRNA effectively initiated DNA synthesis in 
a manner nearly identical to analogous target DNA (Fig. 2.9). Further, these results provided 
additional evidence that the concentration of complimentary DNA and RNA oligonucleotides 
could initiate DNA synthesis in a dose dependent fashion.  
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Figure 2.9. Comparison of miRNA and target DNA Synthesis. Non-denaturing 15% Criterion TBE Gel was run for 
1h at 200V. The gel was then stained with SYBR Green at 10,000 fold dilution in TBE Buffer. A (+) sign indicates 
the presence of indicated reagents at standard reaction conditions (100 nM Capture DNA, 100 nM target DNA, 100 
μM mixed dNTPs, 0.1 U/uL klenow polymerase). A (-) sign indicates the absence of indicated reagents. Numerical 
values indicate target DNA and miRNA concentrations in nanomolar units. A low molecular weight DNA ladder 
was used with standards at indicated molecular weights. 
 
As a secondary means of validating this finding, SYBR Green I microplate assays were 
performed to confirm that target DNA and miRNA could be quantitatively detected in synthesis 
products (Fig. 2.10 & Fig 2.11). Results of these assays were consistent with results of PAGE 
gels, showing clear trends validating that miRNA and target DNA initiated synthesis products 
were produced in a linear fashion, with R2 values of 0.998 and 0.984 for miRNA and target DNA 
linear fits of curves generated between 0 and 50 nM synthesis concentrations. Further, these 
experiments indicated that miRNA and target DNA could be detected with a limit of detection of 
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0.98 nM and 2.22 nM respectively. Notably, these values represent those achieved following a 
10 fold dilution of synthesis samples, indicating that assay limits of detection as low as 98 pM 
and 222 pM could be achieved with undiluted samples.  
 
Figure 2.10. Evaluating target DNA synthesis with SYBR Green I microplate assay. Florescence spectroscopy was 
conducted in black 96 well plates with SpectraMax M2 Multi-detection reader with excitation at 485 nm and 
emission at 508 nm. Data points and error bars represent the mean and standard deviation of DNA synthesis samples 
analyzed in triplicate. 
 
Figure 2.11. Evaluating miRNA synthesis with SYBR Green I microplate assay. Florescence spectroscopy was 
conducted in black 96 well plates with SpectraMax M2 Multi-detection reader with excitation at 485 nm and 
emission at 508 nm. Data points and error bars represent the mean and standard deviation of DNA synthesis samples 
analyzed in triplicate. 
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2.5 RESULTS AND DISCUSSION: HIGH DENSITY ENZYMATIC MICRO-RNA 
LABELING  
While SYBR Green microplate assays provided a convenient and relatively sensitive 
means of quantifying synthesis DNA, our ultimate objective is to quantify miRNA at orders of 
magnitude lower concentration using single-molecule imaging. In order for this to be achieved, a 
robust fluorescent signal must be produced from initial miRNA targets. Beyond the capacity to 
synthesis DNA using enzymatic labeling of miRNA, this process requires that a consistent 
number of labeled dNTPs can be incorporated into the newly synthesized DNA strand.  
As an initial approach to DNA labeling, Cy5-dUTP and biotin-dUTP were each selected 
as initial candidate labels. Deoxyuridine triphosphate (dUTP) was selected as the optimal 
nucleotide of labeling due to the previously demonstrated high incorporation density as well as 
the broad availability of a wide variety of dUTP conjugates.107 To evaluate the synthesis 
efficiency of each of these labels, deoxythymidine triphosphate (dTTP) was replaced with either 
Cy5-dUTP or biotin-dUTP in synthesis reactions conducted with optimized parameters and 
consistent concentration of each of the other reaction components. Results of these synthesize 
were then directly compared to synthesis performed using dTTP. Reactions were then visualized 
using PAGE (Fig. 2.12).  
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Figure 2.12. Evaluation of Cy5-dUTP and biotin-dUTP synthesis. Non-denaturing 15% Criterion TBE Gel was run 
for 1h at 200V. The gel was then stained with SYBR Green at 10,000 fold dilution in TBE Buffer. A (+) sign 
indicates the presence of indicated reagents at standard reaction conditions (100 nM Capture DNA, 100 μM mixed 
dNTPs, 0.1 U/uL klenow polymerase, and 100 nM miRNA). A (-) sign indicates the absence of indicated reagents. 
Numerical values Cy5-dUTP and biotin-dUTP (biot-dUTP) indicate concentration in nanomolar units.  
 
Visualization of these synthesis reaction products demonstrated that samples containing 
miRNA as well as biotin-dUTP produced products in a miRNA concentration dependent manner 
(Fig. 2.12, lanes 10-17). Further, results indicated that bands corresponding to biotin-dUTP 
synthesis products showed an expected decrease in gel mobility compared to synthesis products 
produced from reactions containing unmodified dTTPs. This result as well as the presence of a 
single discrete band is consistent with the successful incorporation of 14 biotin molecules, each 
of which have a molecular weight of 244.31 g/mol.  
While these findings indicated that successful synthesis of highly biotin-labeled DNA 
products, results for Cy5-DNA incorporation indicated lower efficiency of incorporation (Fig. 
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2.12, lanes 2-8). While a clear band was present in reaction samples corresponding to the 100 
nM miRNA sample, this band did not appear to show a gel shift relative to samples containing 
no dTTP. This observation indicated that no significant DNA synthesis products were being 
produced.  
As a secondary means of validating this result, Multi Wavelength Evaluation of this gel 
was conducted to visualize Cy5 within the gel (Fig. 2.13). Surprisingly, visualization of Cy5 
within the gel showed a clear colocalization of a bright Cy5 band with the DNA band visualized 
using SYBR gold. While this finding strongly supports the hypothesis that some Cy5-dUTP 
incorporation occurred during the reaction, the lack of bands corresponding to DNA synthesis 
products as well as the absence of a clear mobility shift indicates that few of the relatively large 
Cy5 molecules (molecular weight=761.83g/mol) were successfully incorporated. This result was 
not surprising as a result of the large molecular weight of Cy5 relative to biotin as well as the 
100% fraction of Cy5-dUTP attempting to be incorporated.99 
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Figure 2.13. Multi Wavelength Evaluation of Cy5-dUTP synthesis. A) UV Evaluation of SYBR dyed Cy5-dUTP 
synthesis products. Non-denaturing 15% Criterion TBE Gel was run for 1h at 200V. The gel was then stained with 
SYBR Green at 10,000 fold dilution in TBE Buffer. A (+) sign indicates the presence of indicated reagents at 
standard reaction conditions (100 nM Capture DNA, 100 μM mixed dNTPs, 0.1 U/uL klenow polymerase, and 100 
nM miRNA). A (-) sign indicates the absence of indicated reagents. Numerical values for Cy5-dUTP indicate 
concentration in nanomolar units. B) Multi Wavelength Evaluation of Cy5-dUTP synthesis. Cy5 Imaging was 
conducted on a ChemiDoc MP Imaging System with Image Lab Software with DyLight 650 nm illumination and a 
Red Epi 695/55 Filter. 
While initial synthesis reactions were not encouraging for the incorporation of Cy5-dUTP 
at high densities, it remained possible that a high fraction of Cy5-dUTP could be incorporated in 
the presence of unmodified dTTPs. While this method would not allow for the incorporation of a 
controlled discrete number of fluorophores, it could provide insight in the design of an 
alternative template sequence capable of accommodating a multitude of Cy5 molecules.  
To evaluate this possibility that multiple dyes could be incorporated in the presence of 
unlabeled dTTPs, Cy5-dUTP and Cy5-dGTP were each used in synthesis reactions at increased 
temperature (45 ºC) with varying fractions of labeled dNTP and dTTP added to bring all samples 
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to a final concentration of 100 μM. Evaluation of synthesis products indicated that synthesis 
occurred in all instances in the presence of even a small fraction of unlabeled dTTP (Fig. 2.14). 
While bands corresponding to a synthesis product was produced in all reactions including dTTP, 
Cy5 imaging of gels indicated that synthesized DNA did not incorporate Cy5 in any case. 
Interestingly, the 100% Cy5-dUTP sample did exhibit a smear of synthesis products co-localized 
with Cy5 fluorescence, indicating that varying amounts of Cy5 were incorporated into synthesis 
products during reactions at increased temperature. Despite the partial success of this sample, 
pursuit of Cy5 mediated miRNA detection was abandoned due to the inconsistent nature of 
synthesis products. 
 
Figure 2.14. Evaluation of the effect of Cy5-dUTP and Cy5-dGTP fraction on DNA synthesis. Non-denaturing 15% 
Criterion TBE Gel was run for 1h at 200V. The gel was then stained with SYBR Green at 10,000 fold dilution in 
TBE Buffer. A (+) sign indicates the presence of indicated reagents at standard reaction conditions (100 nM Capture 
DNA, 100 μM mixed dNTPs, 0.1 U/uL klenow polymerase, and 100 nM miRNA). A (-) sign indicates the absence 
of indicated reagents. Numerical values Cy5-dUTP and Cy5-dGTP concentration indicate the fraction of labeled 
nucleotide, with the overall concentration of dUTP and dGTP remaining constant.  
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While the native PAGE and SYBR Green microplate assays provide compelling methods 
for validating the synthesis products of enzymatic labeling of miRNA, one main drawback of 
these methods is the inability to specifically detect and differentiate between labeled and 
unlabeled synthesis products. While native PAGE can provide compelling evidence of label 
incorporation by comparing synthesis band migration with unmodified synthesis products, band 
migration patterns can be difficult to interpret due to changes in charge density and structural 
influences on DNA gel mobility.  
As a result of each of these factors, it is highly desirable to visualize single stranded 
oligonucleotides independently in to differentiate capture DNA from modified synthesis products 
incorporating labeled nucleotides. While this process seems trivial, the high melting temperature 
and rapid binding kinetics makes distinguishing crisp dsDNA Oligonucleotides a difficult task. 
In order to optimize this process, urea, formamide, and formaldehyde, 3 compounds previously 
demonstrated to facilitate dsDNA melting were evaluated.108–110 As opposed to TBE buffer, 
MOPs buffer was used in these experiments as a result of formaldehyde reacting with primary 
amines in tris(hydroxymethyl)aminomethane present in TBE Buffer. 
Results of denaturing PAGE gels indicated that samples with formamide at a 50% 
concentration, 4 M urea, and no loading buffer exhibited two bands corresponding to single 
stranded and double stranded DNA (Fig 2.15). This finding indicated that only partial 
denaturation was achieved when these conditions were utilized. Of the conditions evaluated, 
loading buffer containing 7.33% formaldehyde and 4M urea proved to be the most effective at 
denaturing DNA despite resulting in partial precipitation of urea as indicated by the presence of a 
white precipitate in the gel loading wells.  
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Figure 2.15. Evaluation of the effect of chemical agents on oligo denaturation. 15% Criterion MOPs urea gel was 
run 50 V for 30min, 150 V for 75min. The gel was then stained with SYBR Green at 10,000 fold dilution in MOPs 
Buffer. Numerical values represent the concentration of each agent with the indicated units. Samples were prepared 
as indicated and denatured for 10min at 65 ºC prior to loading onto the gel.  
 
As a final means of analyzing the synthesis of highly modified DNA, denaturing buffer 
containing urea and formaldehyde was used to analyze reactions products. In addition to 
reactions utilizing Cy5-dUTP, biotin-dUTP as well as alkyne-dUTP were evaluated. Like biotin, 
alkyne modifications can be used to label DNA with fluorophores using a covalent copper free 
click chemistry reaction.111–113 As with biotin, alkyne along with its polyethylene glycol (PEG) 
linker modifications are also very small (104.15 g/mol) relative to Cy5 modifications, a factor 
which was hypothesized to facilitate more effective functionalization.  
Consistent with prior finding, results of this analysis indicated that Cy5-dUTP was not 
effectively incorporated into synthesis products as indicated by the absence of any bands 
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exhibiting a shifted gel mobility (Fig. 2.16). Alternatively, both biotin-dUTP as well as alkyne-
dUTP displayed robust bands with clear shifts in gel mobility, and as expected the larger biotin 
modifications showed a greater mobility shifts than the alkyne-modified dUTP. The intensity of 
these bands, as well as the size relative to unmodified capture DNA also strongly indicated that 
complete incorporation of all 14 potential dUTP incorporation sites had occurred. Further, the 
absence of smeared bands and the crisp nature of modified bands supported this conclusion.  
 
Figure 2.16. Evaluation of DNA synthesis with modified bases and denaturing PAGE. 15% Criterion MOPs urea gel 
was run 50 V for 30min, 150 V for 75min. The gel was then stained with SYBR Green at 10,000 fold dilution in 
MOPs Buffer. Numerical values represent the concentration of each agent with the indicated units. Samples were 
prepared as indicated and denatured for 10min at 65 ºC prior to loading onto the gel. 
 
Together, this research provides the framework for synthesizing highly modified DNA 
from miRNA within a solution. Beyond simply producing highly labeled probes, the control of 
the exact number of DNA modifications through design of the DNA template sequence allows 
miRNA to be labeled in a controllable and uniform manner. Prior to this objective being realized, 
however, robust methodologies for surface modification and fluorophore attachment must first 
be optimized.  
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CHAPTER 3: MICRO-RNA DETECTION WITH FLUORESCENCE MICROSCOPY 
3.1 OVERVIEW OF SURFACE ATTACHMENT OF ENZYMATICALLY-LABELED 
MICRO-RNA  
The initial validation of the production of highly labeled miRNA synthesis products 
demonstrated that the enzymatic labeling process was efficient when using biotinylated 
nucleotides and streptavidin-fluorophore labels. In order to achieve single-molecule detection, 
however, synthesis products must be successfully immobilized to an appropriate surface as 
depicted in Fig. 2.1. As an initial step, DNA is adhered to a glass surface. This is accomplished 
by aminating the surface using (3-aminopropyl)triethoxysilane (APTES) functionalization. 
Aminated surfaces are then functionalized using a 5000 kD linear PEG polymer terminated at 
one end with an amine-reactive N-hydroxysuccinimide (NHS) group and one end with an azide 
for click reactions. This heterobifunctional compound is abbreviated as azide-PEG-NHS.  
DBCO-modified capture oligonucleotides (oligos) are then attached the azide surface 
through strain promoted azide-alkyne click (SPAAC) reaction.111–113 This process can be 
performed prior to any experimentation, and can be conducted on a mass scale. PEG chains are 
used along with the functional azide group to reduce nonspecific binding while providing a 
small, flexible, and biologically stable linker.114,115 DNA modification with PEG is also known to 
increase nuclease resistance in biological fluids.116 Further, PEG has been demonstrated to 
improve specificity and reduce background binding in both bead-based and surface-based 
assays.117,118,119 Together these factors make PEG an inexpensive and effective linker for DNA 
surface attachment. 
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 The intent of this section is to discuss the development of surfaces capable of facilitating 
single-molecule detection of fluorescently labeled miRNA. In order for this to be achieved, 
surface modification protocols were initially optimized and validated. Protocols for surface 
attachment of DNA were then optimized to ensure high capacity loading. Finally, protocols for 
optimizing the attachment of functionalized DNA were evaluated and the capacity for detecting 
densely labeled miRNA was demonstrated.  
3.2 MATERIALS AND METHODS 
3.2.1 Evaluation of streptavidin-functionalized slides 
As an initial step, a humidified chamber was prepared using an pipette box containing 50 
mL of water with wet Kimwipes covering the top surface. SuperStreptavidin SuperMask™ 48 
(Arrayit Corporation, SMSFM48) slides with hydrophobic wells were then blocked by the 
application of 7.5 uL ArrayIt blocking buffer to each well for 1h at room temperature within a 
humidified chamber. Blocking buffer was then removed and the slide was washed 6x with 10 mL 
PBS. Biotin containing samples were then applied to the wells with 4 uL applied per well within 
a humidified chamber. Following a 4h incubation , slides were then washed 6X with 10 mL PBS 
(137 mM NaCl, 2.7 mM potassium chloride, 10 mM disodium phosphate, 1.8 mM 
monopotassium phosphate), were covered with glass coverslips, and clear rapidly drying 
fingernail polish was used to seal coverslip edges.  
3.2.2 Evaluation of aldehyde-functionalized slides 
As an initial step, a humidified chamber was prepared using an pipette box containing 50 
mL of water with wet Kimwipes covering the top surface. Amine containing samples were 
applied directly to SuperAldehyde SuperMask™ 48 (Arrayit Corporation, SMAM48) wells in 4 
49 
 
uL amine free buffer applied to each well within a humidified chamber. Following a 4h 
incubation, slides were washed 6x with 10 mL PBS, were covered with glass coverslips, and 
clear rapidly drying fingernail polish was used to seal coverslip edges.  
3.2.3 Preparation of Azide-functionalized coverslips 
Clean 22X30 mm No. 1.5 coverslips(VWR, 48393 150) or Chambered Cover glass 50 
Well (Electron Microscopy Sciences, 70460-50R) were prepared in batches of 10 coverslips held 
in a glass holder. Coverslips were initially cleaned with 1 M NaOH with sonication for 10min. 
Coverslips were then washed 10X with water, and were dried using centrifugation at 500g for 
5min or through nitrogen drying. Plasma cleaning was then conducted and coverslips were 
immediately transferred into an acid alcohol solution containing 93.46% methanol, 1.87% 
APTES ((3-Aminopropyl)triethoxysilane), and 4.67% glacial acetic acid and allowed to incubate 
for 20min with sonication for 1min after 10min of incubation. Coverslips were then washed 10X 
with water, and were dried using centrifugation at 500g for 5min or through nitrogen drying.  
A 100 mM sodium bicarbonate solution containing 2.375% (w/v) mPEG5000-NHS 
(Nanocs Inc., PG1-SC-5k ) and 0.125% (w/v) Biotin-PEG5000-NHS (Nanocs Inc., PG2-BNNS-
5k) or 0.125% (w/v) Azide-PEG5000-NHS(Nanocs Inc., PG2-AZNS-5k) was then prepared. 
Pairs of two coverslips were then labeled on one side, 20 uL of the PEG solution was then 
applied to the unlabeled side of one coverslip and the unlabeled side of the second coverslip was 
used to create a sandwich between each. Coverslip pairs were then transferred to humidified 
chambers for 3 hours. Coverslips were then washed 10X with water, and were dried using 
centrifugation at 500g for 5min or through nitrogen drying. Coverslips were then stored at -20 ºC 
until usage.  
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3.2.4 Evaluation of biotin-PEG coverslips 
Biotin coated coverslips were bound with Streptavidin-labeled Phycoerythrin (PE) 
(BioLegend, 405203) for 1h hour at room temperature in PBS containing 2% BSA with 4 uL 
applied per sample within a humidified chambers. Coverslips were then washed 6 times with 10 
mL PBS, were covered with a second coverslip, and were imaged immediately. Images were 
taken using a Zeiss Fluorescence Microscope with a 100x objective, excitation with a 561 nm 
laser with 7.9% intensity, 44 degree TIRF angle, 600 nm band pass filter, and indicated 
integration time and indicated EM gain. Ensemble plots of single-molecule and mean 
fluorescence images were created using two distinct plots merged using points within the linear 
range of each plot. 
3.2.5 Evaluation of azide-PEG coverslips 
Cy3-DBCO (Sigma-Aldrich, 777366), DBCO-PEG4-biotin (Sigma Aldrich, 760749), 
Biotin-dsDNA-DBCO (Integrated DNA Technologies, N.A.), or synthesis products prepared as 
described above were added to azide coated coverslips with 4 ul samples added per well in high 
salt buffer (900 mM sodium chloride, 20 mM Tris, 1mM EDTA, 0.1% tween 20, pH 7.4) for 4h 
at a 20 nM concentration unless otherwise indicated. Samples were then washed 10 times with 
10 mL high salt buffer. For samples containing biotin, Streptavidin-labeled Phycoerythrin (PE) 
(BioLegend, 405203) was then added in high salt buffer containing 2% BSA with 4 uL applied 
per sample and incubation for 1h hour at room temperature. Samples were then washed 10 times 
with 10 mL high salt buffer, were covered with a second coverslip, and were imaged 
immediately. Images were taken using a Zeiss Fluorescence Microscope with a 100x objective, 
excitation with a 561 nm laser with 7.9% intensity, 44 degree TIRF angle, 600 nm band pass 
filter, and indicated integration time and indicated EM gain. Ensemble plots of single-molecule 
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and mean fluorescence images were created using two distinct plots merged using points within 
the linear range of each plot. All incubations were conducted in a humidified chamber. 
3.2.6 Image acquisition, data analysis, and statistical methods 
Samples were imaged via wide-field illumination on a Zeiss Axio Observer.Z1 inverted 
microscope with a 100x 1.45 NA alpha PlanFluar oil immersion microscope objective with 
indicated excitation source, filters, integration time, and camera gain. Images were acquired 
using a Photometrics eXcelon Evolve 512 electron-multiplying charge-coupled device  using 
Zeiss Zen software. Images were exported as 8-bit TIFF files with 512 pixel x 512 pixel 
resolution. 
Mean fluorescence intensity values were calculated for each field of view by taking the 
mean fluorescence of all image pixels using ImageJ software.120 Single-molecule images were 
analyzed using MATLAB and a multiple-target tracing algorithm to count the number of spots in 
each field of view.121  
Field-of-view single-molecule counts or mean fluorescence values were then used to 
generate individual sample data points by taking the average of image single-molecule counts or 
mean fluorescence values for 10 images representing different fields of view for a single 
technical replicate. Experimental data points and error bars were then generated by taking the 
mean and standard deviation of values for 3 sample technical replicates.  
3.3 RESULTS AND DISCUSSION: EVALUATION OF DNA ATTACHMENT TO 
CHEMICALLY FUNCTIONALIZED SURFACES 
 In order to establish new protocols for functionalizing surfaces, it is important to first 
understand the benefits and drawbacks of common surface modification methods. In addition to 
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characterizing the benefits of these techniques for use in ultrasensitive single-molecule detection, 
use of commercially modified surfaces provides a convenient means of establishing protocols for 
evaluating successful in-house surface functionalization. To this end, aldehyde-modified and 
streptavidin-coated surfaces were selected for characterization.  
The first surface evaluated consisted of streptavidin covalently attached to a glass 
surface. As previously discussed, streptavidin is a protein which binds to biotin with incredibly 
tight noncovalent interactions.94 To characterize the capacity for these streptavidin-coated slides 
to bind DNA, DNA end-labeled with a Cy5 and a biotin modification was designed (Cy5-DNA-
biotin). This DNA was then used to determine the binding capacity of commercial 
SuperStreptavidin SuperMask™ 48 (Arrayit Corporation, SMSFM48) slides. 
  Experiments were then performed by adding Cy5-DNA-biotin to blocked streptavidin 
slides at concentrations ranging from 3.16 nM to 10 μM for 1h at room temperature. In order to 
evaluate the specificity of the binding interaction, these experiments were also performed in the 
presence of 1 μM free biotin. Results of this analysis indicated that fluorescence signal plateaued 
at 100 nM, indicating that the biotin-binding sites were saturated with DNA above this 
concentration (Fig. 3.1). Further, experiments performed in the presence of 1 μM biotin indicated 
that the streptavidin-binding interaction was >97% inhibited even when the biotin-DNA was 
present at a 3.16X excess. There was still discernable Cy5-DNA-biotin fluorescence when the 
Cy5-DNA-biotin was present at a 10X excess (10 μM), but only 14.9% of that of the sample 
without free biotin. Beyond demonstrating the high specificity of the biotin-streptavidin surface 
binding interaction, this finding provided substantial evidence that the binding kinetics of free 
biotin were dramatically faster than the corresponding Cy5-DNA-biotin. 
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Figure 3.1. Evaluation of Cy5-DNA-biotin binding to streptavidin coated slides. Streptavidin coated slides were 
bound by Cy5-DNA-biotin for 1h hour at room temperature in humidified chambers. Figure data points and error 
bars represent the mean and standard deviation of averaged fluorescence of 10 field-of-view images on each of 3 
technical replicates analyzed independently. Displayed images are representative fields of view selected for each of 
the indicated conditions. A control containing no Cy5-DNA-biotin is plotted as a concentration of 0.1 nM in order to 
visualize the blank on a log-scale plot. Images were taken using a Zeiss Fluorescence Microscope with a 20x 
objective, excitation at 640/30nm , and emission at 690/50nm, 400ms exposure time, and 0 EM gain.  
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The surface binding capacity is an important determinant for any surface used in a 
biological assay, because it determines the total number of binding sites. In addition to having a 
major impact on the upper limit of detection, the overall number of binding sites plays a major 
role in binding kinetics as well as target binding equilibrium. Together these factors make the 
binding capacity an important contributor to the overall sensitivity of tests using different 
surfaces.122,123 Identifying a 100 nM binding capacity for streptavidin surfaces was an 
encouraging finding, as this value corresponded with the capture DNA concentration used in 
enzymatic labeling of miRNA indicating that the entire template could bind to streptavidin 
surfaces without dilution.  
A second metric evaluated for streptavidin slides was the rate of binding for biotin-DNA. 
These experiments were performed by adding Cy5-DNA-biotin at a concentration of 20 nM to 
blocked streptavidin slides at time points varying form 7.5min to 240min. Results of these tests 
indicated that surface binding was nearly saturated at the maximum time point of 240min (Fig. 
3.2). This binding rate was slower than initially anticipated considering the relatively large 
surface area to volume ratio for 4 uL applied to well with a 16 mm2 surface area (4mmx4mm). 
The most likely explanation for this finding is that DNA charge repulsion dramatically reduced 
DNA binding relative to binding of biotin alone.124,125 While ultimate applications of the 
enzymatic labeling of miRNA involve capture of miRNA to DNA which is already bound to a 
streptavidin surface, the rate of DNA binding is an important factor for establishing experimental 
protocols which ensure that DNA binding goes to completion. 
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Figure 3.2. Evaluation of Cy5-DNA-biotin binding time to streptavidin coated slides. Streptavidin coated slides were 
blocked and then bound by 20 nM Cy5-DNA-biotin for an indicated amount of time at room temperature in 
humidified chambers. Biotin control samples are those incubated along with 1 μM free biotin. 0 time controls 
represent background values in the absence of any Cy5-DNA-biotin. Figure data points and error bars represent the 
mean and standard deviation of averaged fluorescence of 10 field-of-view images on each of 3 technical replicates 
analyzed independently. Displayed images are representative fields of view selected for each of the indicated 
conditions. Images were taken using a Zeiss Fluorescence Microscope with a 20x objective, excitation at 640/30nm , 
and emission at 690/50nm, 2s exposure time, and 100 EM gain.  
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 Commercial aldehyde-functionalized slides were also analyzed. Aldehyde groups can 
react with primary amine groups to form covalent bonds.126,127 While streptavidin binds biotin 
with a Kd of 4X10
-14M, covalent bonds are preferable to reversible processes.94 In order to 
evaluate the binding characteristics of aldehyde-functionalized slides, DNA containing an 
organic fluorophore (TYE563) as well as a primary amine was designed (TYE563-DNA-amine). 
The overall binding capacity of the aldehyde-functionalized slides were then evaluated using 
TYE563-DNA-amine applied to slides at concentrations ranging from 10 nM to 10 μM for 4h at 
room temperature.  
Surprisingly, experimental results of TYE563-DNA-amine binding to aldehyde-
functionalized slides showed linear binding even up to a 10 μM concentration with a R2 value of 
0.9943 over the entire concentration range (Fig. 3.3). This finding indicated that the binding 
capacity for aldehyde-functionalized slides was at least a 100X greater than that of the 
streptavidin bound slides. One possible reason for this substantial difference in DNA binding 
capacity is that the streptavidin binding density on the commercially purchased slides is not 
maximized. A second possibility is that the large size of streptavidin protein (diameter=5 nm) 
fundamentally limits the number of binding sites on the surface relative to the size of a single 
aldehyde group.128–130 While the capacity to bind such a large concentration of capture DNA is 
not needed with our labeled miRNA products, these findings exhibit a major potential advantage 
of using covalent binding to adhere capture agents to a solid support.  
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Figure 3.3. Evaluation of TYE563-DNA-amine binding to superaldehyde slides. Superaldehyde coated slides were 
bound by TYE563-DNA-amine for 4h hour at room temperature in humidified chambers. Figure data points and 
error bars represent the mean and standard deviation of averaged fluorescence of 10 field-of-view images on each of 
3 technical replicates analyzed independently. Displayed images are representative fields of view selected for each 
of the indicated conditions. Images were taken using a Zeiss Fluorescence Microscope with a 20x objective, 
excitation at 550/25 nm, emission at 605/70 nm, bandpass 585 nm, 250 ms exposure time, and 0 EM gain.  
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 The binding rate of aminated DNA to aldehyde-functionalized slides was then evaluated 
by adding TYE563-DNA-amine at a concentration of 20 nM to aldehyde-functionalized slides at 
time points varying form 30min to 240min. Surprisingly, surface binding occurred at asimilar 
rate to that of the streptavidin binding to Cy5-DNA-biotin, with reactions each showing 
saturation around 240min (Fig. 3.4). This finding suggested that each reaction had similar 
binding kinetics for adhering DNA to the surface, and indicated that an incubation time of >4h 
should be used for adhering DNA to slide surfaces.  
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
 
 
Figure 3.4. Evaluation of TYE563-DNA-amine binding time to superaldehyde slides. Superaldehyde coated slides 
were bound by 20 nM TYE563-DNA-amine for the indicated amount of time at room temperature in humidified 
chambers. Figure data points and error bars represent the mean and standard deviation of averaged fluorescence of 
10 field-of-view images on each of 3 technical replicates analyzed independently. Displayed images are 
representative fields of view selected for each of the indicated conditions. Images were taken using a Zeiss 
Fluorescence Microscope with a 20x objective, excitation at 550/25 nm, emission at 605/70 nm, bandpass 585 nm, 
400ms exposure time, and 0 EM gain.  
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 Once biotin binding parameters to commercial streptavidin slides was optimized, the 
binding of miRNA to biotin capture DNA was analyzed to demonstrate that effective miRNA 
capture could be achieved. This was achieved by binding biotin capture DNA to blocked 
streptavidin surfaces 100 nM biotin-DNA adhered for 4h at room temperature. The binding of 
miRNA to immobilized capture DNA was then analyzed using a fluorescein-labeled synthetic 
miRNA with a sequence complimentary to the unbound end of capture DNA. 
 Experimental results indicated that, unlike the Cy5-DNA-biotin binding to streptavidin, 
fluorescein-miRNA binding to a capture oligonucleotide saturated within 1 hour with a plateau 
in fluorescence signal occurring at a concentration of 50 nM (Fig. 3.5). This finding indicated 
that, while successful miRNA binding did occur, the total binding capacity for miRNA was 
lower than the binding capacity for biotin-DNA. Despite this fact, miRNA binding showed good 
linearity, with a R2 value of 0.992 between 0.78 nM and 50 nM fluorescein-miRNA.  
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Figure 3.5. Analysis of fluorescein-miRNA binding to capture DNA coated slides. Streptavidin coated slides were 
blocked and then bound by 100 nM biotin-capture DNA for 4h at room temperature in humidified chambers. 
Fluorescein-labeled miRNA was then bound at indicated concentrations for 1h at room temperature in humidified 
chambers. 0 miRNA controls represent background values in the absence of any fluorescein miRNA. Figure data 
points and error bars represent the mean and standard deviation of averaged fluorescence of 10 field-of-view images 
on each of 3 technical replicates analyzed independently. Displayed images are representative fields of view selected 
for each of the indicated conditions. Images were taken using a Zeiss Fluorescence Microscope with a 20x objective, 
excitation at 470/40 nm, emission at 525/50 nm, band pass 525/45 nm, 2s exposure time, and 60 EM gain.  
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3.4 RESULTS AND DISCUSSION: OPTIMIZATION OF SURFACE 
FUNCTIONALIZATION METHODS 
 While commercial products such as aldehyde and streptavidin coated slides provided a 
convenient means of evaluating surface properties and establishing tools for surface 
characterization, these products were not optimal for single-molecule imaging. The thickness of 
glass slides ( ̴ 1 mm) precludes the possibility of single-molecule imaging which requires high 
numerical aperture objectives with short working distances, requiring thin coverslip (̴ 0.17 mm). 
Further, the optimal platform for detecting DNA synthesis products would have multiple distinct 
wells in order to concentrate binding events into a smaller surface area and to allow for multiple 
samples to be measured on the same coverslip. Unfortunately, no such commercial products 
exist, necessitating the establishment of new protocols for functionalizing minimally auto-
fluorescent welled glass coverslips for use.  
 While the previously evaluated streptavidin and aldehyde-based surface chemistries work 
for many biological assays, the inability to successfully incorporate a consistent number of Cy5-
dyes into labeled miRNA products as well as the successful incorporation of biotinylated dyes 
necessitated a surface chemistry other than streptavidin for attachment. While an aldehyde 
surface could have worked for this application, stability concerns for long term storage led to the 
selection of azides as a surface modification group. Azides are a convenient modification 
because of their long term stability, availability as amine reactive N-hydroxysuccinimide (NHS) 
esters with long PEG chains, as well as the availability of DBCO as a modification on 
commercially synthesized oligonucleotides. Azides readily react with DBCO in aqueous solution 
through a covalent interaction known as the rapid copper free  click chemistry reaction.111–113 
Further, prior protocols had been described for the functionalization of glass surfaces biosensor 
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surfaces with a copper free click chemistry reaction following APTES-mediated amination of a 
surface.131,132,133 
 To test the effectiveness of this strategy, a protocol for functionalizing clean glass 
surfaces was developed using APTES amination of coverslips followed by functionalization with 
azide-PEG-NHS or biotin-PEG-NHS (see section 3.2.3). As an initial means of evaluating 
whether successful coverslip amination and PEGylation had occurred, biotin-PEG-NHS was 
used in lieu of azide-PEG-NHS with evaluation using streptavidin-PE at a variety of 
concentrations.  
 Initial analysis of biotin-PEG-NHS-functionalized surfaces using Strep-PE binding 
indicated that fluorescence plateaued at a concentration of 10 nM. This finding indicated that the 
overall binding capacity for the modified cover glass surface was nearly 10X lower than the 
capacity of even the commercial streptavidin slides (Fig. 3.6). Notably, phycoerythrin is a very 
large fluorescent protein (240 kD), a factor which likely played a partial role in limiting the 
extent of streptavidin binding through steric interference. Despite the relatively low binding 
capacity of biotin coverslips, a robust signal was measured, indicating that the surface amination 
and PEGylation processes had each been successful.  
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Figure 3.6. Evaluation of streptavidin-phycoerythrin (Strep-PE) binding to biotin coated slides. Biotin coated 
coverslips were bound by Strep-PE for 1h hour at room temperature in humidified chambers prior to washing. 
Coverslips were then covered with a coverslip and imaged immediately. Figure data points and error bars represent 
the mean and standard deviation of averaged fluorescence or particle counts in 10 field-of-view on each of 3 
technical replicates analyzed independently. Ensemble plots of single-molecule and mean fluorescence images were 
created using two distinct plots merged using points within the linear range of each plot. Displayed images are 
representative fields of view each of the indicated conditions. A control containing no Strep-PE is plotted as a 
concentration of 1E-15M in order to visualize the blank on a log-scale plot. Images were taken using a Zeiss 
Fluorescence Microscope with a 100x objective, excitation with a 561 nm laser with 7.9% intensity, 44 degree TIRF 
angle, 600 nm band pass filter, 500 ms integration time, and indicated EM gain. 
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As an additional finding of this experiment, it was identified that, unlike the glass slides 
previously used, the selected coverslips were compatible with single-molecule imaging of Strep-
PE with a detection limit of 6.76 fM (Fig. 3.6). Moreover, this experiment demonstrated that 
independent plots for single-molecule and mean fluorescence images can be merged using points 
within the linear range of each plot to create ensemble plots capable of detecting Strep-PE over 6 
logs of linearity with an R2=0.9997. In addition to validating the successful surface 
functionalization, this experiment demonstrate a low LOD and large linear range which provided 
encouraging results for the ultimate detection of highly biotin-labeled DNA synthesis products. 
Once existing methods had been used to confirm that the APTES mediated amination 
process as well as the NHS-PEG binding had been successful, coverslip modification with azide-
PEG-NHS was performed. Azide surface binding capacity was then evaluated using Cy3-DBCO 
as concentrations ranging from 20 nM to 500 nM added for 4h at room temperature in PBS. 
Results of this evaluation indicated that Cy3-DBCO binding to azide coverslips remained linear 
(R2=0.997) up to a 500 nM without any indication of saturation (Fig. 3.7). This finding was 
unsurprising considering the small size of the azide functional groups relative to streptavidin as 
well as prior results indicating that aldehyde functional surfaces had an incredibly large binding 
capacity for aminated DNA.  
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Figure 3.7. Evaluation of Cy3-DBCO binding to azide coated coverslips. Azide coated coverslips were bound by 
Cy3-DBCO for 4h hour at room temperature in humidified chambers. Figure data points and error bars represent the 
mean and standard deviation of averaged fluorescence of 10 field-of-view images on each of 3 technical replicates 
analyzed independently. Displayed images are representative fields of view selected for each of the indicated 
concentrations. Images were taken using a Zeiss Fluorescence Microscope with a 100x objective, excitation at 
550/25 nm, and emission at 605/70 nm, 400ms exposure time, and 0 EM gain.  
 
To further characterize the azide-DBCO reaction parameters, the reaction rate was 
analyzed by adding 100 nM Cy3-DBCO to azide-functionalized slides at vary large range of time 
points ranging from 1h to 26.5 h. While prior reports indicated that click chemistry reactions 
were relatively slow compared to biotin-streptavidin and aldehyde-amine reaction kinetics, 
results of this experiment indicated that the reaction was largely saturated after a 4h incubation 
period (Fig. 3.8).134,135  
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Figure 3.8. Evaluation of Cy3-DBCO binding to azide coverslips. Azide coated coverslips were bound by 100 nM 
Cy3-DBCO for the indicated amount of time at room temperature in humidified chambers. Figure data points and 
error bars represent the mean and standard deviation of averaged fluorescence of 10 field-of-view images on each of 
3 technical replicates analyzed independently. Displayed images are representative fields of view selected for each 
of the indicated conditions. Images were taken using a Zeiss Fluorescence Microscope with a 100x objective, 
excitation at 550/25 nm, and emission at 605/70 nm, 400ms exposure time, and 0 EM gain. 
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In order to gain additional insight into the binding kinetics of DBCO-labeled ligands with 
the azide-modified coverslips, a second experiment was conducted using biot-PEG-DBCO added 
at the same time points. Following biot-PEG-DBCO binding, biotin binding was characterized 
through the addition of Strep-PE for 1h in PBS (2% BSA). Surprisingly, biot-PEG-DBCO 
binding saturated after a 1h incubation, about 4 times faster than the Cy3-DBCO conjugate (Fig 
3.9). While explanation for this phenomenon is that steric interference from the larger Cy3-
DBCO conjugate decreased the reaction rate relative to biot-PEG-DBCO, a conclusive 
explanation remains elusive. Together with prior data, however, this result provided strong 
evidence that a successful protocol had been established for modifying glass coverslips with 
azide and selectively immobilizing DBCO ligands to a modified surface. 
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Figure 3.9. Evaluation of biot-PEG-DBCO binding to azide coverslips. Azide coated coverslips were bound by 20 
nM biot-PEG-DBCO for the indicated amount of time at room temperature in humidified chambers. Coverslips were 
then bound by Strep-PE in PBS containing 2% BSA for 1h hour at room temperature in humidified chambers. 
Figure data points and error bars represent the mean and standard deviation of averaged fluorescence of 10 field-of-
view images on each of 3 technical replicates analyzed independently. Displayed images are representative fields of 
view selected for each of the indicated conditions. Images were taken using a Zeiss Fluorescence Microscope with a 
100x objective, excitation at 550/25 nm, and emission at 605/70 nm, band pass 600/37 nm, 100 ms exposure time, 
and 100 EM gain. 
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3.5 RESULTS AND DISCUSSION: DETECTION OF MIRNA SYNTHESIS PRODUCTS 
As a final step in the process of optimizing the surface chemistry and the DNA 
attachment protocol, parameters must be optimized specifically for the attachment of highly 
biotin-labeled double stranded DNA complexes. While experiments conducted with Cy3-DBCO 
and biot-PEG-DBCO showed robust signals after binding for 4 hours, detection of PAGE 
verified biotin-modified DNA complexes generated signals 1000X lower than expected even 
when reacted with azide surface under the identical conditions. To determine if this phenomenon 
was specific to the reaction synthesis products, a model system was designed to determine if dual 
biotin and DBCO-labeled double stranded DNA complexes in the absence of other reaction 
components would exhibit similar inhibition in azide surface binding.  
To replicate a binding complex and signal readout similar to that produced by enzymatic 
labeling of miRNA with biotin-dUTP incorporation, DBCO-modified capture DNA was 
prehybridized to a complimentary biotin-modified oligonucleotide. Biotin-dsDNA-DBCO 
complexes were then incubated with azide-modified coverslips for 4h at a 20 nM concentration. 
Bound complexes were then labeled for 1h with Strep-PE in 2% BSA. Surprisingly, results of 
this experiment showed surface binding at least 3 orders of magnitude lower than the 
corresponding biot-PEG-DBCO signal (Fig. 3.10).  
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Figure 3.10. Evaluation of Biotin-dsDNA-DBCO binding to azide coverslips in PBS. Azide coated coverslips were 
incubated with 20 nM Capture DNA-DBCO pre-hybridized with biotin-labeled target DNA for the indicated amount 
of time at room temperature in humidified chambers. Coverslips were then bound by Strep-PE in PBS containing 
2% BSA for 1h hour at room temperature in humidified chambers. Figure data points and error bars represent the 
mean and standard deviation of averaged fluorescence of 10 field-of-view images on each of 3 technical replicates 
analyzed independently. Displayed images are representative fields of view selected for each of the indicated 
conditions. Images were taken using a Zeiss Fluorescence Microscope with a 100x objective, excitation at 550/25 
nm, and emission at 605/70 nm, band pass 600/37 nm, 500 ms exposure time, and 1000 EM gain. 
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This finding provided significant evidence that the properties of the dsDNA complexes 
were acting to inhibit DBCO binding to the azide-modified surface. A one possible cause of this 
decreased binding is that the relatively large size of the 88 bp DNA complex caused crowding 
effects which result in decreased target binding.136,137 While this hypothesis is possible, the 
incredibly low signal indicates that a very small amount of DNA was being bound. A more likely 
possibility is that the large negative DNA charge results in charge repulsion which dramatically 
reduces the interaction of DNA complexes with the modified glass surface.124,125 It is a well-
established phenomenon that DNA solid-phase binding can be largely dependent on these charge 
repulsion effects.138 Alternatively, low salt in the reaction or wash buffer along with charge 
repulsion on the surface could each contribute to destabilization of the DNA duplex and removal 
of the biotin-labeled DNA.139,140 
In order to test whether charge repulsion was a main factor contributing to the low signal 
observed, azide surface binding experiments were repeated using Biotin-dsDNA-DBCO with 
binding in a solution containing 2M NaCl and a high salt wash buffer (900 mM sodium chloride, 
20 mM Tris, 1mM EDTA, 0.1% tween 20, pH 7.4). Consistent with the hypothesis that signal 
loss resulted from charge repulsion effects, a robust signal was generated with high salt binding 
conditions (Fig. 3.11). While direct comparison of images collected on different days can be 
somewhat inaccurate, surface fluorescence in these experiments exhibited at least a 100 fold 
increase in intensity comparison to results achieved with reactions conducted in PBS. Further 
analysis of binding curves indicated that surface binding reached 47% of it’s maximum value 
after 30min and 56% of it’s maximum value after a 1h incubation. Consistent with prior C 
binding experiments, the overall binding saturated after about 4 h.  
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Figure 3.11. Evaluation of Biotin-dsDNA-DBCO binding to azide coverslips with high salt. Azide coated coverslips 
were incubated with 20 nM Capture DNA-DBCO pre-hybridized with biotin-labeled target DNA for the indicated 
amount of time in 2M NaCl at room temperature in a humidified chambers. Coverslips were then bound by Strep-PE 
in high salt buffer containing 2% BSA for 1h hour at room temperature in humidified chambers. Figure data points 
and error bars represent the mean and standard deviation of averaged fluorescence of 10 field-of-view images on 
each of 3 technical replicates analyzed independently. Displayed images are representative fields of view selected 
for each of the indicated conditions. Images were taken using a Zeiss Fluorescence Microscope with a 100x 
objective, excitation at 550/25 nm, and emission at 605/70 nm, band pass 600/37 nm, 100 ms exposure time, and 
200 EM gain. 
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Initial experiments evaluating the impact of reaction salt concentration on dsDNA 
binding indicated a strong NaCl concentration dependence for conjugation of Biotin-dsDNA-
DBCO to azide-modified glass surfaces. While this experiment strongly suggested that binding 
inhibition for dsDNA was caused by a charge repulsion effect, high salt concentrations were 
utilized in both the surface DBCO-Azide reaction solution as well as for the post reaction sample 
washes. As a result, it could not be determined whether the nature of NaCl dependence 
originated with Biotin-dsDNA-DBCO binding to the azide surface or through denaturation of the 
biotin-labeled target DNA from the DBCO-labeled capture DNA covalently attached to the azide 
surface.  
To further elucidate the origin of the salt dependence, a second set of experiments was 
designed to evaluate the Biotin-dsDNA-DBCO surface binding concentration dependence for 
monovalent (NaCl) and divalent cations (MgCl2). Prior studies have demonstrated that divalent 
cations such as magnesium are much more efficient at stabilizing DNA duplexes than 
monovalent ions such as sodium.141 This effect is so robust that even 15 mM Mg2+ has been 
shown to lead higher hybridization than even 1 M Na+. While this phenomenon has a dramatic 
effect on DNA stability, monovalent and divalent cations are expected to perform in a charge 
dependent fashion with respect to shielding charge repulsion between unbound DNA molecules. 
By comparing the specific nature of divalent cation DNA stabilization to the effects of 
monovalent cations, a greater understanding of the cause of signal inhibition can, therefore, be 
gained.  
To explore the impact of different cations on dsDNA binding, the monovalent NaCl 
concentration dependence of dsDNA-DBCO binding to azide-functionalized surfaces was 
evaluated first. As opposed to using pre-hybridized biotin-dsDNA-DBCO complexes for these 
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experiments, enzymatic labeling of miRNA incorporating biotin-dUTP and using a DBCO 
conjugated capture DNA was used. Results of this experiment indicated that biotin-dUTP 
synthesis signal increased as a function of the salt concentration added, with a maximum 
fluorescence 76X higher than the 0 salt control achieved at a 1 M NaCl Concentration (Fig. 
3.12).  
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Figure 3.12. NaCl concentration dependence of the binding of synthesis products of enzymatic labeling of miRNA 
azide coverslips. Azide coated coverslips were incubated in a buffer containing the indicated concentration of NaCl 
as well as 20 nM dsDNA complexes prepared with biotin dUTP synthesis products of enzymatic labeling of 
miRNA. Samples were incubated for 4 hours at room temperature in a humidified chambers, and were then washed 
with the indicated buffer. Coverslips were then bound by Strep-PE in high salt buffer containing 2% BSA for 1h 
hour at room temperature in humidified chambers. Figure data points and error bars represent the mean and standard 
deviation of averaged fluorescence of 10 field-of-view images on each of 3 technical replicates analyzed 
independently. Displayed images are representative fields of view selected from samples with high salt wash buffer 
for each of the indicated conditions. Images were taken using a Zeiss Fluorescence Microscope with a 100x 
objective, excitation at 550/25 nm, and emission at 605/70 nm, band pass 600/37 nm, 100 ms exposure time, and 
1000 EM gain. 
 
 
0
20
40
60
80
100
120
0 500 1000 1500 2000
M
ea
n
 F
lu
o
re
sc
en
ce
 (
r.
f.
u
.)
[NaCl] (mM)
PBS
Wash
High
Salt
Wash
77 
 
Along with evaluating the NaCl concentration dependence of synthesis product binding, 
evaluation of the impact of wash buffer salt concentration indicated that use of a high salt wash 
buffer (900 mM sodium chloride, 20 mM Tris, 1mM EDTA, 0.1% tween 20, pH 7.4) also had a 
robust impact relative to PBS. For samples washed with the high salt buffer, the relative 
fluorescence signal was found to be 34X larger than for corresponding samples washed with PBS 
(Fig 3.13). As a result of the covalent nature of DBCO-azide binding, this finding indicated that 
a main determinant in signal inhibition was the destabilization of biotin-labeled synthesis 
products during washes with PBS.  
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Figure 3.13. MgCl2 concentration dependence of binding of biotin synthesis products of enzymatic labeling of to 
azide coverslips. Azide coated coverslips were incubated in a buffer containing the indicated concentration of NaCl 
as well as 20 nM dsDNA complexes prepared with biotin dUTP synthesis products of enzymatic labeling of miRNA 
DNA synthesis. Samples were incubated for 4 hours at room temperature in a humidified chambers, and were then 
washed with the indicated buffer. Coverslips were then bound by Strep-PE in high salt buffer containing 2% BSA 
for 1h hour at room temperature in humidified chambers. Figure data points and error bars represent the mean and 
standard deviation of averaged fluorescence of 10 field-of-view images on each of 3 technical replicates analyzed 
independently. Displayed images are representative fields of view selected from samples with high salt wash buffer 
for each of the indicated conditions. Images were taken using a Zeiss Fluorescence Microscope with a 100x 
objective, excitation at 550/25 nm, and emission at 605/70 nm, band pass 600/37 nm, 100 ms exposure time, and 
1000 EM gain. 
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As a secondary means of evaluating the nature of the salt dependence of synthesis 
product binding, the divalent cation concentration dependence of dsDNA-DBCO binding to 
azide-functionalized surfaces was evaluated using MgCl added to reaction solutions. Consistent 
with the findings for NaCl, this experiment showed a clear concentration dependence, supporting 
the conclusion that a high salt concentration was necessary for successful attachment of the 
synthesis product. Further, it was found that a 250 mM concentration of MgCl2 resulted in 
binding analogous to that achieved with 1 M NaCl (Fig. 3.12 & 3.13). This finding strongly 
suggested that DNA duplex stability played an integral role in surface attachment of stable 
dsDNA complexes. Additionally, findings indicated that use of high salt buffer washes increase 
the signal generated by 10X relative to the use of PBS.  
Together, these results provided strong evidence that high salt was required in the surface 
attachment buffer as well as for stabilizing the dsDNA complex during sample washes. Results 
also indicated that the divalent cation Mg2+ performed as well as Na+ even at a 4X lower 
concentration, providing additional evidence that DNA duplex stability was a main factor 
impacting signal generation. While it remains possible that the presence of cations also 
facilitated the azide-DBCO SPAAC reaction by increasing shielding between negative charges 
on the surface, additional validation experiments would be required to conclude that this was the 
case. Independent of the primary source of the observed phenomenon, salt dependence 
experiments conclusively demonstrated that the usage of high salt buffers in surface attachment 
and complex wash steps could facilitate the generation of a robust Strep-PE signal.  
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With establish protocols shown to enable dsDNA-DBCO binding, the binding time for 
enzymatic labeling of miRNA products was then evaluated. As expected, the binding of 
synthesis products in high salt conditions proved to be very similar to the binding of biotin-
dsDNA-DBCO complexes, with signal reaching 76% of the maximum value after 1h and 
saturating after approximately 4h (Fig. 3.14). With this metric identified, an optimized azide 
surface attachment protocol consisting of a 4h incubation of synthesis products in high salt (2M 
NaCl) was finalized for usage with DBCO-functionalized capture oligonucleotide used in 
conjunction with the surface binding protocol for conjugating the products of enzymatic labeling 
of miRNA optimized in section 2.5 for generation of highly biotin-labeled DNA.  
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Figure 3.14. Evaluation of biotin-dUTP synthesis products of enzymatic labeling of miRNA binding time to azide 
coverslips. Azide coated coverslips were incubated in a buffer containing 2M NaCl and 20 nM dsDNA complexes 
prepared with biotin-dUTP synthesis products of enzymatic labeling of miRNA. Samples were incubated for the 
indicated amount of time at room temperature in a humidified chambers, and were then washed with the indicated 
buffer. Coverslips were then bound by Strep-PE in high salt buffer containing 2% BSA for 1h hour at room 
temperature in humidified chambers. Figure data points and error bars represent the mean and standard deviation of 
averaged fluorescence of 10 field-of-view images on each of 3 technical replicates analyzed independently. 
Displayed images are representative fields of view for each of the indicated time points. Images were taken using a 
Zeiss Fluorescence Microscope with a 100x objective, excitation at 550/25 nm, and emission at 605/70 nm, band 
pass 600/37 nm, 100 ms exposure time, and 1000 EM gain. 
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The overall assay performance was then evaluated using azide-modified coverslips to 
capture highly biotin-labeled products of enzymatic labeling of miRNA validated using PAGE 
electrophoresis. After synthesis and surface attachment, DNA complexes were visualized by 
labeling with Strep-PE and visualized using TIRF microscopy as described in Fig. 2.1. In 
addition to evaluating the trend generated from the mean image fluorescence, images were 
analyzed to count individual particles, and ensemble plots of single-molecule and mean 
fluorescence images were created using two distinct plots merged using points within the linear 
range of each plot as demonstrated for use in quantifying low abundance Strep-PE in Fig. 3.6. 
Results of this analysis showed a clear concentration dependent trend of the strep-PE signal 
exhibiting a linear trend with an R2 value of 0.988 (Fig. 3.15). Under these conditions, products 
of enzymatic labeling of miRNA could be detected between concentrations of 316 pM and 31.6 
nM, and a limit of detection of 388 pM. While the sensitivity of this assay was lower than 
desirable, the demonstration of successful detection of the products of enzymatic labeling of 
miRNA provided the fundamental framework for subsequent assay development. 
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Figure 3.15. Quantification of biotin-dUTP synthesis products of enzymatic labeling of miRNA. Azide coated 
coverslips were incubated in a buffer containing 2M NaCl as well as an indicated concentration of dsDNA 
complexes prepared with biotin-dUTP synthesis products of enzymatic labeling of miRNA. Samples were incubated 
for 4 hours at room temperature in a humidified chambers, and were then washed with high salt buffer. Coverslips 
were then bound by Strep-PE in high salt buffer containing 2% BSA for 1h hour at room temperature in humidified 
chambers. Figure data points and error bars represent the mean and standard deviation of averaged fluorescence of 
10 field-of-view images on each of 3 technical replicates analyzed independently. Displayed images are 
representative fields of view selected from samples with high salt wash buffer for each of the indicated conditions. 
Images were taken using a Zeiss Fluorescence Microscope with a 100x objective, excitation with a 561 nm laser 
with a 2.9% intensity, 44 degree TIRF angle, band pass 600/37 nm filter, 400 ms exposure time, and indicated EM 
gain. 
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To gain a more extensive understanding of the synthesis product fluorescence labeling 
state, individual particle locations were identified and particle intensity values were analyzed to 
determine whether streptavidin-PE bound to the products of enzymatic labeling of miRNA 
exhibited higher fluorescence intensity then Strep-PE alone (Fig. 3.16). Results of this analysis 
indicated that synthesis products exhibited nearly identical fluorescence signatures, however, 
indicating that synthesis particles were likely only labeled with a single Strep-PE. As a result, 
single background Strep-PE binding events could not be removed using thresholding to improve 
assay sensitivity.  
 
Figure 3.16. Evaluation of PE particles for biotin-dUTP synthesis products of enzymatic labeling of miRNA. Azide 
coated coverslips were incubated in a buffer containing 2M NaCl and 10 pM biotin-DBCO or 10 pM dsDNA 
complexes prepared with biotin-dUTP synthesis products of enzymatic labeling of miRNA. Samples were incubated 
for 4 hours at room temperature in a humidified chambers, and were then washed with high salt buffer. Coverslips 
were then bound by Strep-PE in high salt buffer containing 2% BSA for 1h hour at room temperature in humidified 
chambers. Images were taken using a Zeiss Fluorescence Microscope with a 100x objective, excitation with a 561 
nm laser with a 2.9% intensity, 44 degree TIRF angle, band pass 600/37 nm filter, 400 ms exposure time, and 
indicated EM gain. Individual particle locations were then identified and particles intensities were evaluated by 
taking the average intensity of a 3X3 pixel square around the particle center. This process was conducted for 1000 
individual particles and values were normalized to the image background intensity. Particle intensity averages and 
standard deviations were plotted in the table.  
One of the most likely causes for the less then optimal sensitivity achieved to date is the 
occurrence of background strep-PE binding, a factor which limits the detection of single-
molecules below the threshold of nonspecifically bound Strep-PE molecules. While the limit of 
detection for Strep-PE alone has been shown to be possible over 6 logs extending down to 6.76 
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fM, the use of Strep-PE to label another components necessitates that Strep-PE is at a 
concentration orders of magnitude above the limit of detection. As a result, some level of 
background binding will limit any assay measuring single Strep-PE molecules.  
The enzymatic labeling of miRNA platform does, however, have the capacity to 
circumvent this limitation by thresholding out background binding of single-molecules. While 
the present assay parameters remain limited by high fluorophore background binding, the 
fundamental design of the enzymatic labeling of miRNA platform allows for the production of 
highly labeled DNA synthesis products. Although the existing template design has been shown 
to bind only a single Strep-PE, there are a variety of ways to increase labeling including the use 
of longer template DNA as well as altering the design on biotin incorporation sites to facilitate 
improved streptavidin binding steric hindrance. By incorporating a multitude of fluorophores for 
each enzymatically labeled miRNA, this method would ultimately allow binding events to be 
distinguishable regardless of the level of individual Strep-PE background binding. By leveraging 
the power of this method, the present platform has the capacity to increase the sensitivity by 
orders of magnitude, and ultimately to the single-molecule level. 
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